Professional Documents
Culture Documents
2 (
!
!
) ".#. 2551
$ 2,000 %&'
"*"+ -
%/
-'!
%#3
!
!
#$%&$' ($)
&* %+
& !,(
--%+-!./ (
0&%&
$
!!
&*
)
&*1$$-$
22$
%&!$$(
-%&3/
%+
&2$!/
22$45
# $ /
22$*672
'
-$2 $*.6
22$- %- '
'-'%
$+ %$$8 %
'4 9-$ -%!45 !(32
2/ -
--3%&'3 -$&
07 0' %&-
2
-+3 (4
5 # $!8. 2 :$ %&6
- % &-
&0+2.2
- (
$ ,
) &(--7%!$, DOTS %&$*,3 )
$! $:+&$
$4-4 -%&, %&
!$$ %&3!
$'3 -$& ( -+3/ % &
%
$
-%4%
'
& -;21; $-5 -8 6&! %& -
&-4
&;
+3 1
5
%1!
$
-
&0+ 5-
3 % -%
'
: / 2!./ +3 ('
%(%&
< !2 !
(
1
-%
-7$& %&
&$',5
" %
1
1.1 3&1
1.2 %+
&2$$
1
1.3 8,
1.4 EF&3/$(
&*1$
&
1
1
1
1
3
4
4
5
7
11
12
14
14
14
16
22
22
22
22
22
23
23
23
16
17
18
&
31
31
33
34
38
39
46
47
48
53
53
54
55
60
60
61
59
59
70
70
73
65
66
74
74
75
75
&
77
77
77
78
84
84
84
88
10
?
#/9+.
'"*?
- ! %+
&2$%& '3/
-
22$-4
%+
&2$'3/
-
22$-4
'3/
-
22$$ !45 '3/ 2&$
#$
- $, -%+
&2$'3/(8+$
1. 2 (Administrative control )
2. -0+%3. -
F&
91
91
91
92
92
92
92
94
95
97
97
100
102
12
,
/
12.1 & $%&$
12.2 * -
106
106
110
A
1. $
%&--$
2. % ],-%&$
3. Check lists *
113
117
135
1.1
(Tuberculosis
TB)
Mycobacterium
!"#
$%&#'*
M. tuberculosis !+ M. africanum *,&-
.
! M. bovis /
&,&!0 123
/-23*,4/*/*,56
Mycobacterium !/7,3,,
Mycobacterium
8 *,&9/
123 /*/
&,
/ Atypical Mycobacterium
Mycobacterium other than tuberculosis
(MOTT) &$" Nontuberculous Mycobacteria (NTM)
3*:/
&,
/#/%
$ &
3;, 8 * Mycobacterium Auium Complex (MAC) &5<,
*
1.2
##
7
35<, = /
5<, = *
, /
#
<& ?
#
3
(Droplets) #&7,!<
7
3"* ,*#
<&
&23
Primary focus
*!<
/+
37
+&,
/+
372 / Primary
focus #
/+
3 72 Primary complex
3*://3 10% 7
35<,
#=
123
43
&*/! 0
20-30 J
/:*, !"
5<,
/!"74#4</, :#*/=
&337,/5<,
/4</,3 (
4#7!
KK)
!=
:/72 ! "# $"%
&%"'(&"% ) *$
1.3 "+#
!+%3
$%!9!"7
!"7
3=#& 8
#' !" +&,
//%
$ &/
3#7
3
!0 / #
,- #33
, !35&,#7
3//"3/ /72 #3
/; .'.2536
30
/ :*,#'&,
<& 4#Q"Q! #,
3,*7
33
!-0
7
3&$"
30
/3 1 & 3 7
3#
, /" (Prevalence) 7
35<,=/#/ 14-15 , #/2323
"/
+3
(Highly infectious) ##J/5 <, = &/ (Incidence) #/ 9.2 , 95%
<&
#' +3W 5<, = ! J##/ 1.7 , (98%
<& #' )
37
3
30
//
J .'.2008 &"/ 22 #'/ %
$ #/
80% 7
35<, =
<& 22 #'3 #*,/
#'/ +5<, = //+ 123 3
#'/ 5 <, = /! " &
<&
*, #'
1 !+#'*
<&
18 +3#&37
3
30
/ 0 #'*#/
5<, = &/" #4 J# 90,000 (142
!#) ##/ 40,000
5<, = !/#
(62
!#)
!+7
3#'* #7
3#' 25-30%
, 3 506 7
3
!+# &
5 //
/;/ #!94 #'*!/-"/
*, +5<,=!/#/33 /
/#7
3
!0 &J .'.2547 /
5<, = / 72
&!/# #/ 50
!#
"+#) ,
"#
# 11 ,
3
!0 #
/ &"/ 5<, = /
" #
3 15-49 J 9%
!0 /, &7#&
./ #7
3
!0/! " !<3
-23 31% #5<,=!3/
!0/,-23 12% !5<,=
!0!3/
11%
!+!-0
!0&#'* 3 / /#7
3
!07,/&#'*&
J .'.2527 7#/!#!/-23 J .'.2547 #/5<,
*
3! #/ 1 ,';
!*, 5 ! 33/5<,
*
/
< 5 !'; #5<,=
!0/&37
3!+
# /
/,
,
# 30
&"/5<,=
!0/
Q
! Z
Q
!/!"
"/ !+
!0 #
3'!/90 #!+3[
3"/"7 /
;5<, = /"/ *,+?[#3
!0&5<, = &/ &
3#7
3
!0
!0&5<,=/,/!<3 Q#&7 10 123
"/#&334
/ #7
3
!0/! " /! !7
3
!0&5<, = !<3! " #/ 2 7
3Q 7
33 #' '2;&37&% 15
3 # #'* &J 2550
*
&5<, = &/ #/ 20%
1.4 -/
&0&
!+ /"/ *,+?[#3
##' 3 3 !"/
3!/#
5<, = / ; 33 8 "4&#'* 5?[#33 1
123 +&J .'.2540 - 2541 &5<, = &/ /
;7&723
25.4% #
7 (MDR-TB) 2.01% #/
+3 2 &J
.'.2544-2545 /
;7&723 3
14.8% #
7 (MDR-TB) 0.93% &?[#3
3 3 /
7&5<, = * /;/
1.65% !3#'* $%
&5<, = */;/
3*/!3< /
3*:/
'2;&"/ #'; *, 5<, =
<&
+ 3&7/
3&% #
/ #7
3
!0!3< 123
"/ #/ %
$ &"/
]/4</
!<3-23 5-7% #&5<, = *, /
(Acquired drug resistance) :
!<35<, =
&/
" 5
1. #3!9!"7. 3# : "9'!05!/5!+3#
!0#
!0
"/#[
3&5,<
*
&#'* /03 2 "3K :
3/0'! !+3#"9'!3, 2546.
2. 3?[#33#, !+#.
3. Global tuberculosis control: surveillance, planning, financing. WHO report 2005. Geneva,
World Health organization (WHO/HTM/TB/2005.349.)
4. Payanandana V., Rienthong D., Rienthong S. et al. Surveillance for anti tuberculosis drug resistance in
Thailand : Results from a national Survey. Thai J Tuber. Chest Dis. 2000 ; 21 : 1-8.
2.1 ,&6#7
", (Global TB Control Strategies)
"90 DOTS
"90
30
/ *,!
#&,#'3 8 +*+
"/
/ #!94&;#
[
3
7#/ #'3 8 +"90*
&,/ 150 #' !+#'**,+"90/&,3 .'.2539 /& 8
+4
+
3
#7!/-
"/ 3 #'&J .'.2545
&J .'.2548
30
/ *,!
"90" (Stop TB Strategies) #+
123 /
7,372 #/
/ 72 #
,
1. Pursue quality DOTS expansion and enhancement 32-
"90 DOTS
"/
#
/72 #,3733 72
30#
3 5 *,
Political commitment with increase sustained financing ,&,/!+% /
3#// 72 #3
&+3"/&,/ #!94
Case detection through quality-assured bacteriology ,=&,
&,
3Z / ##"4 !/#,,
3"'0 ##
&3! /-+*,
Standardized treatment with supervision and patient support &,;5<, = ,##
/] /3/<#!!";
&,5<,=*,
3
3+
Effective drug supply and management system /
3
##!!"
/#!94#3
<3#3
!0
[
3#"/
7
"/&5<,
, 373 5<
, #"/ ! 3
8
3. Contribute to health system strengthening (!!"#!"74&,7,/7:3)
&,///
5&,7,/7:3 / " 3#/
W
&, #"3#7,
/<7!
/33"/7,<5<, =
8
37,*&3!9!"7 ]
8 &"/ 3
//#:
,
4. Engage all care providers (#!3"3 7,
3!"74)
#!3#337
34], ##337
34]
(Publicpublic and Public-private Mix : PPM)
/]<5<, = #!" (International Standards for TB care : ISTC) +
72
3Z&Q#;5<,= 123#!/-!3!/<
!+,,! 9!"77
333 8 3 4]#
5. Empower people with TB and communities
#", &,/!+%!
!"/#!3/
&,/ /<, #/##
/! /&"/ Q#&5<, *, /-237/37
3!3/
5<, = (Advocacy, Communication and Social Mobilization :ACSM)
Community participation in TB Care "//! /&<5<, = *, &,/<, 5<, =
#% &,/<, /" !3!/
!!/&
3
6. Enable and promote research (!3!/'2; *, 3Z &+3
"/ '2;
9 &/ 8 & Q
#&/ #W1
,
2.2 "5) :7;!
53"/3
/ 533 (National Tuberculosis
Programme : NTP) !+#'* *,+72 3/!+,#
3
#3J.'.2503-2507 !3
#
< 3 &7/
3#
#' 533//337
3#5,<%7
3
30
/Q 8 /
J .'.2507 (.'.1964) #,
373<3"/7,
!9!"7 ]/
< ,
&,
"/#*, #' 3 / #
53-
/
&,9 30 3 &,*,5*, #5,< = #
" 7 2 3#
< ,*,
#! +%
7,
23 :
,
3
/#7,-23//,
3 7
3
#, #3!9!"723*,+/5333 J 2510 123 Z
5!+:&<Q1 1 !9!"77
3#3!9!"7&33 8 123
!"#$%!& '()*+,(&$-#- .+$/+!00* 1 '.2
*,5&3/
"/#[/
:
7,3#
/*,7
"/
#:,
3
&, &,
Q#&
!+,=#;,5,<=
/<3&,!-
%,
1.2
7
3!/# (Conversion rate)
! +%
33/
;
!/-3
!-0*,: ,
7
3!/#&5,< = &/#
1+
*/+ 85% !+5,< = #4
8 */+ 80%
"#$% =
#$%
&
$' #*
! #+,$
() X 100
!
()
1.3
; (Completion rate)
()
!
()
X 100
1.4
7 (Default rate) /[/+33
, 3*/
, 5%
,
X 100
1.5
,/ (Failure rate)
,/&;5,< = &/!/#
*/ 3%
$%
1.6
(Death rate)
-
1.7
.
;7; *
, , , !,
"!
#$
2. 55;*
2.1 /
"/7
3,= (Case detection rate)
!+%
23&
53"/ WHO +;/#!94
, /
"/7
3,
=&/*/,
70% 7
3+5,<=
!/#
#/
<&"/ (123$"&,
+*,!<7
3 WHO)
$
+$"
% =
-. ,#$%
/%$ 2
/
3 X 100
-. ,#$%
/%$"! %$,
,$/
3
10
2.2
J (Case notification rate)
3
-23,/7
3,=
/
#0
3 (
, J) #3
/100,000 #
2
3/100,000
2.3
+//"
"#'
3
-23,/7
3!-0
&/" #
"*///,/3# 3 -23#
, 3 &7#
7
3
&#! 3<
"#, ##! 3<
"! &%#
/J
!J, /,
&'#%3*/3/ !!
/
%3/ 8 #/&,&!
*/7,/7:33
&7,
! /-+*,
3,=
4
2.4 !!7
35,< = !/#&5,< = 3 / /
3,
!&7,
##/
1 : 1 /! ! !/#/ 8 #-23 Q5 (Over diagnosis)
#,#
" #$%
#$%
/
3
-. "! %$,/
3
2.5 "47
3!/#
!
"47
33&!< ,
!/#5,< = /
!3!#&,5#/ 10% (8-12%)
"#$%
#$%
2
X 100
$ #"# #$%
11
12
' !
. #3
3,
" 4
3
&,?!
"!9!"7&7# ' (On the Job training)
2. ,/#/5 2#3
+##
+4
/+3
3
4 3
3,= 35!/#'
/
! !"##7,/7, 35; #3+35!/5!#
!07
3
+4
#!3&,5,< #!3#3
3. ?[#3/!-0#
+4
13
14
" 5
1. #3!9!"7. 3+3"/3. 3/0"/"/!0;3
#'* +. 2541
2. !+
*. 3!
</
!,3!/4</,"/ : 3/0!+33/0
30
!3#05'2, 2548
3. Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs. WHO, August
2004 (WHO/HTM/TB/2004)
4. Expanded DOTS Framework for Effective TB Control, WHO : 2002.
5. The Stop TB Strategy.World Health Organization, 2006 (WHO/HTM/STB/2006)
15
/]!
<; *,W72/"3/
!!"/!#7
3
5<, Z 3 &4]#4
#*,&,<;5<, =
!3!#=
&"/
"
3/
" 4 123 /3 5<, = 5 !/#,,
3"'0
#
; #
/
*
3 5<, Z
3,
3
3 (/3
3,
1
3:
,) #&,5
43!3
357,*, 123 */!35
!
3
;,Z# (/" :
3#4 fluroquinolones /9
/5+&,5<,=72 23*/&,) &5<,=
3 -,#+*,!3!/## 3
&"
!3!
*
/&,*,5 Q
16
17
Q
!
,
7M&% 14 #/40
#+&5<, = *, ;/
/
#! / 5!
CDC
: Centers for Disease Control and Prevention (USA)
ATS
: American Thoracic Society
IUATLD : Interantional Union Against Tuberculosis and Lung Disease
KNCV : Tuberculosis Foundation (The Netherlands)
WHO
: World Health Organization
18
19
7. !9&*, <!"74/
" 4!<3&!4#,
/! / ,!!"
,+3&
#"/
3. )5 7E,)"
. !9&*,7,
/<7!<;/
< #/5
/
#&, 3 33#3
,
/ 7,
3
7. !9&*,3 # #/#!/7
3!4#30
,
/, Q + (/:&+7
3 #
&
) #7,
!
&
3
;-
&,-23/!3/
#3
/#!/
. !9 #
#7&,7
3& 8
9 133 8 ! 3 ;5
#57,33
#/ #5#
*,
!4##;
8
3. !9&7,-237,
/<30 7,
3!47
35<, = #; #!+
7
3330-, ,
35<, =
"* , /
+5<, =
. !9 ## /<, #!0
#5<, =
8 #2;!/&
/
&:*,3Q*-23!!";
4. &,
. !9&*, /:30#!
3 7,-23330&
7. !9#
/
Z!9;'/ -,;&,
!3
**,
#&,*, -235/33/#30 #
**, 4&
7
3
. !9 #
#/! &53 */
5
<;
5. 75
. !9&*,
/!" /
-
3'! #W9/
7. !9&;/ 7,
3!4#30 7,
/< 5
,,
8
7 2
< /
/7
35<, =
6. 76 7
. !9&,
35
33 &,/* ,!+-"#!303 ,,! 7" 4
#,
3&,+,
3*,
3"9/
7. !9 #
"90
,, #! 3< 72 -,,
33*/*, #,
3
*,,35
;0
;
7. #
. !9&7,/
3
307
3
#!!"
W!/!#!//7
3"/ 535<&, ,!"74 ,, #!//
20
#*,
,
2. &'7@
. /5
&+/#;* ,!3 #3, #
/Z /
#
3
[
3!"747
35<, = #
8
7. /5
#,35<&, ,!"74-23/+ #$%&+/
;
-,/;!&3*/7,&
3,/,3
3. !;, ")=
) !7!
. /5
&
/
< 7
3"/ 5<
, &,7
+#+3
0-,/
7
3
7. /5
!3/
&&!
!97
35<, =
8 #5<&, ,!"74
7,&
]/#]-
7
3"/
4. 7"7
. /5
39/ #!3/!/ 5<, =
8 /,*,
!<
7. /5
39/ /Q !37,
/<7!#/<, * , #3
;#/+%
8 &"/ +&,/
+
#**,:
. /5
39/#/&//#+&,"/'
3+&,
/3 !!"5&,/+&"/ &0&&%7
57+ LJ% ,
"7+
77ME,@
3
456 7 8 5
9%"*+%!"#$%!& :"!%;!+;- <$+ '()*+,(&$-#- =!+* 1 9:'=2
21
!"#$%
"#"& ' () ""&$*
&'+'
",!
!-' .
#
%'%
/* -"&$*
!$%
0 ',
!56
$%-'& & 7%'
.
4.1.2
"# (Active case finding)
0 $% %'
-56 ! /6 30 ,
#
4()
)0 &&56-'&7
*
-
/
.
,8
+#
+-
/&
*# ',
!0
+' (Cure rate)
/) 85 ()
/
,8),'&($%0
+'!
/) 85
56 & ' #&* &&!&+/ ,
* /-
.
!"$=> *&
*
,8!)/
*
7 / ?
/ !56
5%!)'
4$% )*
/ %+, '
' () ,8 '* 0)*
/
'
0 HIV
4.2 $$
,8$%' 0 -
0 '// 2 '= 0 ? &-'0
,)',
&0 , /
)
- (
4&/
. 0)0) -
)0' (Haemoptysis)
.&, !'
22
/*
) -'- -
/!/),
2. '"+ $'
%&
0 $%%'')*)3= !
1
).
0
$
10,000
1))=# -1# % &
0
(/ ) 50 (/" !
$
0 /"6 # 500,000
1))= 0
/
%&
0
"# ) 99.95 "
$
0 / 10,000
1))= %&')*)3=
)
(/" ! %'
)
0 . /!
=%-'
#
3. %- , %
!(/J& 3 ' 0
, 1 !56
.&
(Spot sputum) &!/ ()/
, 2 !
-%&) !56
.&
0 0
/)
(L> &!/ (),
/ (Collection sputum)
, 3
4/
Spot sputum
.&) ,/ 2
/()
/$'
.&
/"6
,8
/ ? & /"6!J& "-'
"*/ (Specimen) '*$. - %=!5)5')'-' 0","
&/
/$'%5
6
J&
),'&'
1. &!56
!
/
*5)
.&
() - () &!"6
2. !56 &! '/
0 -
/!
3+
23
3.
R'Q"()
.&Q- /
7 "!56
4. &!56 - (!'R ()
6' '+
.'05
.'/) -" 6
06'!)# ? ) ! /6 ()(-!
#
)')
0 -'
()!"# '
QW)// ? )/!
-))!"
/"/
1.
XY
-'
/ 5
).
5. '6
.&-'
! -''
) +$
4
0
4/*
)0
0
-
/!/,)1#!0
4L "
.&-'-
/"60
- !56
.&
() "56-
/
"--'! 2-3 !56
06#/
#/-!
/
56 -
/-0-()-
/
!'
0 ,
? /(6 )-0!,
)/0,
)0) 0!
7') ,
)0
)')
. * !56 -/(() &
-' '/!56
,!
*!3 + )!Q
0
')
& ? .,!56 &
-'' #
6. R'Q"
!(/()/J& -
/
"/-' !
.&!
.
() /!"6 ((''/
7
&6'
/
)
. ((/.
%&
0 $%-' %'
')*)3=) )
0! ''&/6
%$'"+ 7
%#8
9
%$'7
(Direct smear)
%'!-
()T)&(5/ -)'=
%'
4
!
4 / ' () '
.
",-'!"&$*
* '& 5)&
0 $%# /6 & ,
0 !
. J& 0
0$%!
-
/
/ '
)0
T& -)'=#,8
"
&
$-
/
0 0
0 ,
T. -
/&0&
0 -' #,
4
)0
/ /
0
'*
0 /
4
0
/*
) &
0 -'/ #
9
%$' (Concentrated smear)
%'5/
/
'
/,!
0
,
(),
>\'
0>\
7
T&
(5/ -)'= ,!&
0 -'/ # (/ !
0 >\
( >\
6"# 3000 xg # ,
!
0 '#
/
%'!
( ,!!0 ,L5
,/!)' -
/
Clorox
/5
Sodium hypochlorite
$) 5N10 %'5
)!
$
/
/!
'
$ 5 (),
>\ !
0 Centrifuge
. 3,000 &/0
&
4/
Relative Centrification Force (RCF) -'
/& 3,000 xg 0
/
4
) 15
0 !
0 $%
!
,/! (),
T& -)'=
0
,!
% &
24
')*)3=
4'*' !7$%'
,!56
'-')/()
"#56/
4$%'
/#
56 $%'
4$%'/
' %$' %%
:
3
/
)'756! (/
0&
-/$'
1.
.&
(
.& (Spot sputum)
0 56
( %'!,( ,
!
.&
" 6 (/56 ' : !56 6')
!
.
) ! # ()-
)
-'
() &/
- '
0-
/ -
/
.&
!
/
2.
&)&
!56 )&&
0
.&
(Early morning sputum 0 Collection
sputum) "'
%',( ,
0
,&56 /
0 0 -
/&
/
.&
3. )56 )&
/
()
.&
56 %'
'&
.&
4. !,( ," 6 !
.&
(/56 ' :
.&
!
' '0!
3
"/
'() ((''/"#
"56 -
/
"
.&
$ -' !
.&
3
,T
)&-)'= 1 (5// 1 /
-!(/#,-)'=
-5/&
)-L (Fix) 2 N 3
,)
)0%'
50Q> "-
/ ,
)
0 ()
(&&L=
6()/-)'=() (&&L=
-/
)*)3=
0 ')*)3=/ -
(5/ -)'=! !T
4-)'=!
/ () !
' -
/
,)&
)!!
/
%'"&
)*)3= "-)'=
/ 2 -)'= !5)&
56 "6,(
456
& '
56()
+ /-.
"
+$%/
+
0 -'! &&"6/-
%$'"+ 7
*
"+
%#7$ 8
0 //-
/
"')*)3=-'
0
$() 6 ='
0
0 $% %''&*$
&
()
0 '&
-
0 /+,&!
4(!+/
0
QT '0
0$%!*
0!0
3+
7
/!
0,
('
4
25
0 >\
.6(&&,
.-' %'
.&-
/,/ 3,000 xg /
0
,'
0
XY 0 ? ! !) ) 4% NaOH
0 / Ogawa media !,&
',
"Ogawa method"
""/
0 ,'
XY ())& Ogawa -'%'
(/,& Lowenstein-Jensen (LJ) ,/5 / ,'
0
XY 0 ? () ->\ )',)
_/
0 0 , Phosphate buffer '
0 >\
.6 / "/
0 ,'
XY ())
& LJ
"Petroff's Method" ' 0
%&
0 -'
#
*"+ Ogawa method
J&
'0
1. *$=
0 ! () ,
- , 4% NaOH _/
0 ()
-
)
0 3% Ogawa Medium
- Pasteur pipette _/
0 ()
26
0'/
/ !
/ 4% NaOH
4 2
/
$
R'Q'/
)'!(/
- 5
!
'&
0
/5
vortex mixer () - 15 %'!
0
/
4 ?
-
0 &
)! Pasteur pipette 0 Transfer pipette '6'() !/
,'
0
XY ()')& 3% Ogawa ' ? ) 100 ul (
$ 4 ')
- ,
6 &
0 *$6
37oC 8 '=
- /5)*'=
8
0
'#
- ))
0 () ',
&0'
0 $%/-
*"+ Petroff's Method
J&
'0
1. *$=
0 ! () ,
- , 4% NaOH _/
0 ()
- Pasteur pipette _/
0 ()
- Transfer pipette _/
0 ()
- '( Mac-Cartney
- )'),&>\ Q
)
* 50
)))
-
)
0 Lowenstein-Jensen medium
-
0 >\
.6
.&-
/,/ 3,000 xg /
2. J&
- ',
'& Ogawa method &,'
) ,'
0
XY ', 4% NaOH 15
-
0 ,'
0
XY 0 ? & 15 () !
,) # _/
0 ()) !)''&
"#'&
50
)))
- ,->\ '
. 3,000 xg 15
-
,!// & %'!
,
)0')''&
$ 0.5
)))
-
! ' ()! Pasteur pipette 0 Transfer pipette '6('()
-'')& Lowwnstein-Jensen medium 2 ' ? ) 100 ul (
$ 4 ')
27
- ,
6 &
0 *$6
37oC 8 '=
- /5)*'=
8
0
'#
*"+ (Incubation)
&
0 Primary culture *$6
6 &%' - 6/ 37oC ()
.*$6
6 &
4 ,*
%'
*'&#*$6
! (/)
0 &*
,6 &
:5*"+ (Culture reading)
/
0 Primary culture (
/
0 5/&
0 -() 3-5
0 '6)*
/
0
(Colony)
4
8
. (Repid grower) () /
/*'=
4
)
8 '=
& (/
&
0 !))
0 !
*')
0 %'
7 "& 8 '=()-
/
)*
/
0 !
.#/ "No growth" &#!/5)-'(/
1. (Growth rate)
0 (
0
4 2 )*
/ 0
-
8
&%
. (Rapid grower)
/ 7
-
8
&% (Slow grower)
/ 7
2. ,)*
/
0 (Colony) &&
3. )*
/
0
8
- Non pigmented 0 Nonchromogen )*
/
0
(White), (
(Buff),
(Cream)
- Pigmented 0 Chromogen )*
/
0
)0
)0/
('
6 0,)/
- Scotochromogen )*
/
0
4 Pigmented
0 &
0 - !
'0 () / ()
#
0 "6(/
4
)
2 '=
- Nonphotochromogen )*/
0
4 Non pigmented (
"6(/
4
)
2 '=
4. )+$ )*
/
0
- Eugonic 0 ( ' 2-3
.
- Dysgonic 0 )
(&
& ' 1-2
.
28
-'& $%
4
0 /
B8% &
7
1. 56
)() 5)J&
-'&$%'
2. 56
5 )
-'& $%'
3. 56
5 )
0 /&
0 $%
29
$
1.
* 6 $%J& ,
&$%(/
3- ! &
6"
= %
=(/
*)$=
), 2529
2. (',
'6$%(/, ,%
'= $% () %'/
3
=
= 4,
2547 %
=3 ISBN : 974N297N224N9
3. &88 8=,
* 6 ()
=
8
0 $%!$%
&$%(/
3- ! &
6"
=
= 4
2542 %
=(/*)$=
)
+
2542 : ISBN 974-331N083N5
4. Kawai M., and A. Fujiki Minimum Essential of Laboratory Procedure for Tuberculosis Control. The Re
search Institute of Tuberculosis, JATA, 1988; p.53-54
5. Kubica GP., Dye WE., Cohn ML., and Middlebrook G. Sputum Digestion and Decontamination with NAcetyl-L-Cystein-Soduim Hydroxide for Culture of Mycobacteria. AM.Rev.Respir.Dis. 1963;87:
775-779.
6. Kubica GP., Kaufman AJ., and Dye WE. Comments on the Use of the New Mucolic Agent, N-Acetyl-LCystein, as a Sputum Digestant for the Isolation of Mycobacteria. AM.Rev.Respir.Dis. 1964;89:
284-286.
7.Petroff, SA. A New and Rapid Method for the Isolation and Cultivation of Tubercle bacilli Directly from the
Sputum and Fecae. J. Exp. Med. 1915;21:38-42.
8. Van Deun A. and F. Portaels. 1998. Limitation and Requirement for Quality Control of Sputum
Smear Microscopy for Acid-fast Bacilli. Int J Tuberc Lung Dis 2(9):756N765
9. Vestal A.L. Procedure for the Isolation of Mycobacteria DHEW publication No.(CDC) 79-8230 U.S. Dept of
Health Education and Welfare Public Health Service. Atlanta, Georgia. 1978. P.129-130.
30
0' &&+!
5)+
&&
2 1#
"&
6)"&*(/!
4-!(
2
'
0
5)
3
,(56
4 (&& '/-
1. ,(
4$%
2. ,(
5)
3. ,(
*(%
4. ,(
+!'
1. %-'
, <
7 (Pulmonary Tuberculosis : PTB) 0
$%!
0 ' "&
5' /
,
)0 ' (Mediastinal and/or hilar) 0,!
0
* ' (Pleural effusion) %'-
/
&(5)!
0 ' '/!6
$%' (/" &$%
0 '/
& 0 ? ,(
4
$%'
7 (Extrapulmonary Tuberculosis : EPTB) 0
$% 0 ?
!/
0 '
/
0
* ' /
,
)0 / &&
'> 5 '6()
0
*
7# &
0
0 ? ()
'!& 3) /
&(') 1# (=
' !+' &&+$%
2. %-'5$'
4,(
56$%'-'&
() &
1
='
/
'
0' &&!
31
.&
-'0!56
'.
).
/-
/-' (This group includes cases without smear
result, which should be exceptional in adult but are relatively more frequent in children WHO/CDS/TB 2003.313)
%' -()!0
/
' /56
&/
65% 56 $%' ()
$ 50% 56 $%*
(/ )&!0
&'
'=/
'
3. %-' '#
56 $%'*(
"# 56 $%
"# ()
/
/
32
2. <=- (Relapse)
56
+$%() -'&7/() 0&+&() (/)&
4$%%'
5)&
0 $%' Direct smear () /0 Culture
3. ;=-%
' (Treatment after failure)
56 +' Category 1 (/5)
0
'0 5
4& 0)
4
& Remained positive) 0)&
4& (Become positive)
56$%
)&
0
+
0-'&+(/5)
0*'
'0 2
)&
4&
56
+' &&+1, ))
)/ &&+
/
4. ;=-%7
(Treatment after default)
56 )&
+ )'+-
/ 2
'0'/
5. (Transfer in)
561#&%"&)0%'#
&() -'&+() #
6. +, ? (Other)
56 $%-
/
"')/
*
!)/
* 56 ')/ /56 )/
*
/ : Bacteriologically negative relapse (M-C-)
56 - '& +$%) 0/
/ 1
'0 %' -
/
#
&!(5$%(/
/
Chronic case -'(/ 56
0 *'+1,()
4&
5.2
;5
6
!>*&
!+$%
6
1#
"+56 !-'
0& 100 %
56& &,'
,
.!+56$%!
/
"T)
)
()
'$%'0 () 56 -
/ *=
% +56 ! ,#"# /-
1. !"6 '() , &'
_ /
0 !$ & '
*'
8
&%
0 1# '!''# -
/
" +$%-' !
4 && '
! &&
" 6 () -
/ +56 $%'
' +$%'
&
0
2 !
Initial phase 0 Intensive phase 1#
_
/
0 $%
0&
'/'
. ,!56
(/
0 ) ! /
0 (Continuation phase) !/ 2 1#
_ /
0 $%
)
)0/6
0 T)&
41,
%' -56 $%'
&
0 -'& () 2 '= (!
%')
,
0 $%!
)')
"'
0 5/'-' (/"
4
0 $%'0 )
0 $%!
)')/
,&56 $%-
/
8
> '0 ) (56
)+() 2 '= .
8
> 0 ?
33
4,
4/'6()/
)0!56+/
# ,%'3
) ' &&
+ $ %' && (&&
) (DOT) #
4 ,
J & % '
. * ' #
( ,!56 !
0!5 R'
6 $ -,
4 ,%'
7 !/ &
0
!
5.3
'L
, "
;
,8 '* !+$%!>*& 0
-%1- ' (Isoniazid : H)
-(L
R1 (Rifampicin : R)
1-
'= (Pyrazinamide : Z)
.%
1 (Streptomycin : S)
(
&6) (Ethambutol : E)
-
/!
)/ %'
7 R () S !+%0 %
'
0
%(&
)5
!
.'# ? (Fixed dose combination)
/ -%1- 1' + -(L
R1
(HR) 0 -%1- 1' + -(L
R1 + 1-
'= (HRZ) 0 -%1- 1'+-(L
R1 +1-
'=+
(
&6) (HRZE)
FDC *%"
5 :"7
/ 7
&*
=S,
- DOT
':7
7
'L
! &&+$%!(5$%(/ (NTP)
! NTP
&&) ? /6 4 && '
34
-
-
!"#
$
!%#
- &'(#)#
- * #)
!%
#+ #
-
(&,
. /#
&
.0%1
&,0%1
&2"# 2
#!*)#*&
&,0%1
&2
04 / MDR-TB
-
/
- &'(#)#/
-
!% & #!%
"
II
III
IV
2HRZE(S)/4HR
2HRZES/1HRZE/5HRE
2HRZ/4HR
# 7
1. Category 1 (2HRZE(S)/4HR)
! 2
'0( ! 4 H, R, Z, E (0! S ( E) *
/
Initial
phase 0 Intensive phase
,8
('"# && () && /'
(/
0 -'' (To cut off chain of transmission)
,&! ) 4
'0
/ /
0 (Continuation phase 0 Maintenance phase)
!
2 0 H, R
*/-.' 56
8( ,! HR
4 7 - 10
'0 !$
4$%'*(
/
dissiminated TB, $%
0 *
, $%
'
0 HIV /
', $% '6,&$%
35
8
> '0
/
+
()) ((56 R'
6))
56/ /
&56 MDR-TB,
-
/
,
(, DOT -
/') !,/
4 Failure () ! CAT4 (/
!0 (
'6()+56 $%'0 )
&*
% $*) "/-.' (=
%)( ,!! CAT2 &56,)+' CAT1 ()
5)
0
'0 5
4& 1# ! CAT4 (1) 0 CAT2 ! $
4?" ,8 /
0
0 () '&
- (DST) () !+
5) DST /-
$! && Intermittent !/+ /
0 0! H () R '=) 3
(2 HRZE/(S)/4 H3R3)
0 )' "&)() 56 ! ! &&
)
%'' H
4 10
./. () R
4 10
./
!$
456
Meningitis, Disseminated 0 Spinal Disease with neurological
complication,
/
0 4
'0
4 7 - 10
'0 (
7
)+
' 9 - 12
'0)
.'
(Fixed dose combination
/ Fixed2, Fixed3, Fixed4 $!!(5
$%(/
)2
+= (evidence base) / ,! Compliance '# 56 #!
/
. '
# FDC
$
* '
0 "0-' (
/
Bioavalability, Bioequivalent ' )
2. Category 2 (2HRZES/1HRZE/5HRE)
3
'0 %' 2
'0( ! 5 0 H, R, Z, E, S /' 4 0 H,
R, Z, E 1
'0
/
0 ! 3 0 H, R, E 5
'0
!$5 )
0 *'
'0 3
4& !*' 2 N 3
.&
/
0
() '&
- ()+!
1
'0 %'! 4 H, R, Z, E
0 *'
'0 4 "
4& /'&
-()! HRE /&
"5)
4&
0*'+
'0 5 0) !/56
4 failure
((/ -
/ ,/
4 failure) 5) DST /
0
'0 2 (3) 0/ DST
0
'0 5 $
'
! HRE /-/5) DST 1# %' -5)-'& ! 3-4
'0 )/ "5)
DST ('/
resist / H () R ('/
4 MDR-TB ! HRE ! Continuation phase /
-
/-'5)
$
/! ,/
4 Failure ()#
&
4 Other (chronic) () !+(&& MDR-TB (CAT4) (/"
5)
'0 5
4& ()
)2/
6) ( '/56 /
4 Failure
/
)
36
3. Category 3 (2HRZ/4HR)
2
'0(! 3 0 H, R
/
0 ! 2 0 H () R
4
) 4
'0
$! 2HRZE/4HR
4! Category3 -'
/
56!$/-
-
/
E
/
. 56$%',
-
/&
0, (5)-
/
-
/
(5)%!' () 5)
0
-
4)&
.
456-
/
"0
0
6)
&
.
.
5)'&
-
0 / ('/
0 -/ H, R, Z
4. Category 4 (Second line drugs)
4! ,& Failure case
4 MDR-TB () Chronic case )0 ! Second line
-
/
!
/ (/ 4 # -) () # ! 4
47'
)7'
4
) 6
'0
() +-
// 18
'0 (/
!06/
0((/,&+$%'0
)
&*
%)
"-
/
"! Second line -'
0
!
/()-
/-'5) 0
*' !+(&& &
7
: ?
7
$-5
6 Y: (
#': 14 [)
'
,/+
< 40 .
40-50 .
> 50 .
H ( .)
R ( .)
Z ( .)
E ( .)
S ( .)
300
300
300
300
450
600
1,000
1,250
1,500
800
1,000
1,200
500
750
1,000
37
1.
1 )*+ &#*2
!
#
2.
2
?'"
.
% DOT
3.
% &#
+ 1 (&% &# *2
#! 1 (&%
1.
1 )*+&#*2
!
#
2.
1
.
% 1 DOT
3.
% &#
+ 1 (&% &# *2
#! 1 (&%
2
?'"
(
!/ (
2
.
!! @)
1
! <!
<
.
% 1 DOT
$*)"
! <! <
.
% 1 DOT
38
1.
$*)
.
% 1 DOT
2.
% &#
+ 1 (&% &# *2
#! 1 (&%
-
DOT
- ! "#$%
%
* &&'
('
&
%)+
!"# $ ) %,
#.
/
%% '
%
+
#0 (
&"1
#2
+3
39
* %4'
5
& DOT '
!"# $ 6)#
%
* &&'
('
&
%)+
('
!"# $ ,7 (retreatment) #.
& 3
, !"# $
) !"# $ #.
7 (relapse) !"# $ , (failure) !"# $ + > 2 '
,
(TAD.SS positive)
40
41
56 */
+ (
!56 $%'
/ 4
/+560 /+
0-'& 2
'0 (0 3 0 4
'0) !
'0 5 +
()
0 *'+ 56
4&!
'0 5 +0) !',
/-
(!
(
0 (&/
& (= !(= J& , (Standing order) !
$*
05!6 DOT
.&
,'')//6-'
) %'-
/ (= (/)
%-
:5
6
7$' 7':7
S %;
2 7+
&& /
,
'0-
/ 5)
4)&
(= ,56 %')
'
7
7/
4$%
5')'(/5)
4& ,(56
4 Failure () #
&
4 Failure ()
+'
&& CAT2 /-
\$-5
6
,7
0 &
*()
%
!56 )&
+/ %'
,
'!(/56
#
42
7-%7'+, 5
6
7
506' , 5 765
6
CAT 1 , 7
< 2 &#
+
/*2
CAT 1 *
2-8 &#
+
/*2
) CAT 1
Treatment after
default
Treatment after
default
-
) CAT 1
< 1
#!
> 8 &#
+
*2
< 2 &#
+
/*2
2-8 &#
+
*2
1-2
#!
> 8 &#
+
*2
CAT 1 *
CAT 1 *
""
)
1
#!
) CAT 1
Treatment after
) CAT 2
default
Treatment after
CAT 1 *
default
CAT 1 *
-
> 2 #!
/*2
2-8 &#
+
*2
*
-
) CAT 2
CAT 1 *
Treatment after
default
Treatment after
default
) CAT 2
> 2
#!
> 8 &#
+
*2
CAT 1 *
43
506' , 6 765
6
CAT 2 , 7
< 2 &#
+
/*2
CAT 2 *
2-8 &#
+
/*2
) CAT 2
Treatment after
default
Treatment after
default
-
) CAT 2
< 1
#!
> 8 &#
+
*2
< 2 &#
+
/*2
2-8 &#
+
*2
1-2
#!
> 8 &#
+
*2
CAT 2 *
CAT 2 *
""
)
1
#!
) CAT 2
Treatment after
) CAT 2
default
Treatment after
CAT 2 *
default
CAT 2 *
-
> 2 #!
/*2
2-8 &#
+
*2
*
-
) CAT 2
CAT 2 *
Treatment after
default
Treatment after
default
) CAT 4
> 2
#!
> 8 &#
+
*2
44
CAT 2 *
506' , 7 765
6
CAT 3 , 7
< 2 &#
+
/*2
CAT 3 *
2-8 &#
+
/*2
) CAT 3
Treatment after
default
Treatment after
default
-
) CAT 1
< 1
#!
> 8 &#
+
*2
< 2 &#
+
/*2
2-8 &#
+
*2
1-2
#!
> 8 &#
+
*2
> 2 #!
/*2
2-8 &#
+
*2
> 2 #!
> 8 &#
+
*2
Treatment after
default
Treatment after
default
Treatment after
default
Treatment after
default
Treatment after
default
Treatment after
default
CAT 3 *
CAT 3 *
) CAT 2
) CAT 3
) CAT 2
CAT 3 *
CAT 3 *
) CAT 2
CAT 3 *
) CAT 2
CAT 3 *
%-5;
0*'+
45
3.
' (Treatment failure)
56
&
0 7/
+ () 5)
0)&
4&!
'0 5
+0)
56
)&!((/)&
5)
4&)+-' 2
'0
4. $6Y
(Default)
56 '
2
'0'/
5.
(Died)
56 $ +$% (-
/,#"#
*)
6. (Transfer out)
56%-+0%'-
/&5)+
$::5
6
(Refer)
!%0//56 !(&&L=
//56 $% (TB 09) %'(/!&/' :
!56"0!& TB09 LT-
&56, /,
!& TB09 -"&%-+$=
()
.&,
TB09 () - "%
S
5;$-5
6
,
+$:: \ 7
"
4%!,
' (. "# .) -
/ #
&!
/0,/
(//
(&&L=
+-!"&%
/
"
4%/,
/ !-
/#
&56 ,&,
%(/!#
&56 ,&,
&%%'!,(56/
456!
/ 5)+ "6%',
&%
"
4%/,
)
!-() 5)+,
% 56
4 Transfer
out () ,
&% #
&56
4 Transfer in
0*'+5)+ "6/,
& %-,
% 1# ,
%
) 5)+ Transfer out -
5)
+- '& (
)/%'*0 5)+ ',
%',
#
&56 (
/
'
0
4)
)
/*!'
5)+#%56-+/,
!$
,
4 ?
/
5.6 76; :'# ^Y&*
5.6.1 765
6
, 08
!+$% & %' &&-
/
Aminoglycoside, Quinolone (Ofloxacin,
Norfloxacin)
! Pyridoxine (
& 6) ) 10
.
0&,*=
46
5.6.2 ; 5
6
"56,))- (Haemodialysis) /6
"!*-'
"-
/-')-
(Haemodialysis)
"! INH, Rifampicin () Pyrazinamide -'%'-
/)'') ,&
Streptomycin () Ethambutol )'')
Creatinine clearance () '
5)(
0 (0')
)! (Increase the dosing interval)
)''
5)/
'&!
)0' ,!,
--' (Too low peak serum concentration) !56)/*
1#3
6)
Creatinine clearance &!'
INH
R
Z
E
SM
K
PAS
Cycloserine
Ethionamide
5-10 ././& #/
) 300 ./&
10-20 ././&
20-30 ././&
15-25 ././&
0.75-1 &/&
! 20-40 ././& #/
) 1 &/&
0.5-1 &/&
! 20-40 ././& #/
) 1 &/&
8-10 &/& (200 ././&)
250-750 ./& (15-20 ././&) #/
) 1 &/&
500-750 ./& (15-20 ././&) #/
) 1 &/&
5.6.3
5
6
. "56
'%&(/5)
)0' &/ ,&
"!*'-'
. "56
%&()
5)
)0'5' )/0
"/ SGOT/SGPT 6 (/ / 3
//! 2HRE(S)/7HR 56
8&(
,/ "
456 6* (
?) 0
8
> &0 $! 2SHE/10-16HE
)
"/ SGOT/SGPT 6
/ 3
// ! 2SHE/16HE
. 56 6!/ Acute hepatitis ()
Jaundice ! SM () EMB -/ Jaundice
- ! INH () RMP
!$5 6
active TB ()
*( !)*
/ Quinolone
(
/ OFX) %'
)! SM () EMB -() 2-3 '= 0! OFX, SM () EMB -
?
5.7 =
+$%
,!(1/ ? '# /-.
56
+
7 '
5.7.1 %/
'6/
,!
0
* ' (Plural effusion) 0)
!/
0
* ' (Pneumothorax) 0-
/
-
/
! Paracetamal
,
)
!/
0
* ' /(=
0 +
,!
0
* ' /(=
0
&,0! Steroids
47
5.7.2
%7
/56
0
*
"56
,!
0
* ' 0)
!/
0
* ' /(=
"56 6&&*
4)')
&
0 !*'&* "56 !'/
0
()
' (Wheezing, $!+&0')
5.7.3 '+7
"56 -
)0'
+!%&) $!)'- (
/
Codeine 30
. ) 3 ) () J
&/( ) "56 (- !
*'(- "
)0'-
/
+
( ,!56
? (
& '//
4
* -
4
)0'
5.7.4
'+, ', ;
+!%&)() $! Steroids !/ ?
&/
5.7.5 7"+7=
!J
5.8 ':*S $ 8%"
(&/-'
4 2
-'(/
5.8.1 ':*S $ 8, 7%"
1. Isoniazid -
/# = & -'(/
Peripheral neuritis /!8/
'!56
*% 0
(%
'
& /)/(6 )
/ !56
& =0
4%
-
4 )-
'
',! Pyridoxine (Vitamin B6) !/
)')
' / pyridoxine 56
)
0 )
/()
0 /
'-
/# =
"T-'' ! Pyridoxine /
-& Isoniazid
+/& &-'
$) 2 56
'! 4-8 '=)
()
4
# '&
-1
= transaminases &!
)0'0*( "#
&
& (Hepatitis) .-'
-
/# =0 ?
4 & -'(/
450
4- '&
,
Frozen shoulder, Eosinophilia, Thrombocytopenia
4
+/ && ) ,!
'
# & 1#
)
0 *0
4
-
/# = T () (--'' Pyridoxine
/
'&
' Peripheral neuritis
2. Rifampicin -
/# = &-'(/
&&
' ,!
')0 -()
-'(/&-
/&/
()
-
/*(
48
+/& /!8/
4
,! '&
-1
= Tranminases & 0 '&
Bilirubin !
)0'6#
/
'&
& !56
>
,!
'
5'
/ 56
%&/6/() !566*56
Alcoholic
'
4
3+
FluNlike syndrome
'!!'6() !(&&
(Intermittent
schedule) 0-'& -
/
,
/!8/
')-'& '/ 3 - 6
'0-() ()
(') 1-2 %
J-'(/ -
'
0
)
0 '6()
)0-/
'
)/
--'
! 12 %
J6
-
(Hyersensitivity reactions) ,!
'
4-
50#
Eosinophyllia thrombocytopenia, Hemolytic anemia ()
' .
4
-
/# =0 ? & -'(/ - /
) '
50 #
'
0/
' '3+
# &
)
0)
4
3. Pyrazinamide -
/# = &-'(/
+/& /!8/
4
,! '&
-1
= Transaminases &!
)0'6
#
&
'&
& /-.
'6, &
49
$ # %$
Streptomycin
Streptomycin
Ethambutol
!*&
!*&
Rifampicin
/
). -
/
5 0 )0 -
). > ()
0
4('
4
"!+
(5
'
-'
%'-
/ *'0!+
%'&!56
!() !,)!
2. $
'-
/# =
)."#) () & ,56&
&
)0!+
5.8.4 %7':*S $ 8%"
50
* +
&
+
!" ( (=25%())
1. 2
&
Challenge HZR R #.
&+
& '
'
Z
2. 2 !'
!
Challenge E R H Z
51
$
1. &88 8=,
* 6 ()
=
8 (&$), 0&$% 7&&
=
4 (7&&&*)
&$%(/
3- %
=* )$=
) .3.2542.
2. &88 88=, '' 3, &*8/ * ()
* 6. (!$%
() % 2534, 2: 57-59.
3. 8.* 3. !+$%() '
+$%.
&&
',
&*
$%' DOTS. ,&
) $%, 1-2 () 4-5
+
2545. %(
16 =
4. 3 '
' (
, 2542). J6 &*
$%(!
/&
) ,
,&56 $%
%&)!3+ 21 $
3=
)
!
/,
) 3)() ,&*
%'/
10
&&
J&
52
! "$# %&
"'("# ((!()*) +
(
,("!
-(( -("!
.
( /#0
1
1,2
(
$((34
. 15 2507 (.<.1964)
1 Fully supervised treatment (
((3( ,
# B*((
14,C (National Tuberculosis Programme : NTP)
DOTS !"E<21"# ((3 2
(
. 15 2537 "H# , 0) (2 1
3,"E,H
"# ! (
!
3- (I00!( 5 23
/# 1(
# 0
3"<1 (
3IJ3!(
'(,((3-((
,0
! 0$
.
!(1 (3
4
#!-H-
<K
,0-H
#1)1 (!(1 ((.
1 "!(1 (
H
# ! " (Stop TB Partnership) /# $-
( (Expanded DOTS Framework)
# 5 2545 V(
23
- 6 23
- !"E<2! (Stop TB Strategy) /# $
1 (""# 2 3
""# 3 1 H
# ,'(,(
-31,!"E<2 DOTS !H 1$(. :1.
*),3)"#03H,#
'(31,( H
#"'
53
<
"
4. 1( 0(333(.
V("# 30
2 1
!
'
,(-*) + 1"# (
DOT) ((. V( ,E "# *V("# (10( #' (
-
333.(K((.0$H[(H
,E
3!
2 4 DOT (*((
! ^3((.
"0# 3('333(. ($. 4 ,E" 0# 1 *) + $
,("# (103$1*
"1"
4 DOT "# *
$
3 100
01*)+ $
,("#((.( (
#0
333.(K((.
H 1*) +
-
$
1
,($1-((
!
,(-(( H3
-$1H
32
#
"!
!
1(
'( V(1 (
0$ 3 40 - 50
-
1 (
0
"'*
1
,
. -4
.
""# 'V(3""# !
. -(( (Multidrug-Resistant Tuberculosis : MDR-TB)
/#
. 1$$(3,3$]_/(, 1
(#
$1
$
MDR-TB (
0
54
6.2.5
(/
,
13. (41 "# 3
("
3"# )1
-*) +
""# '( (*) + ,() H
# ,1""<H"2 0
*1("(1 (
-1"#
"# )1
*) + 4 1 ,
3
1*) + (
,1 ". 3("# ^H3(
DOT
0
(*)+ 1 (
1( (( 03$*
1
,0
*,(
/#
034
4
,
3"0
1
V(
( 1 3
,
"#
'0 41(
41
IJ!-*)+ (
0*
((
{{
6.2.6
*) +
,($1 3
(
41( -(($ (/"# _ $ -(
(
-,
(Accessibility) 3
-*) + (Acceptance) V( :5%!
%' ,$/0
!%9A%$4
A!&54
!:5!*-$ ,$/0 %9%9
&&
$ , !
CE*EA
4
!94:5*! $- *;%$ %
%'&!$
!"# $
$%&
'
( )*+
55
%&
"'("# ((!(
*) +
DOT $" "
0("$#
2.3 < 1
*((
#( "#00("#"# 41 "'("#
DOT 41( 0
*((
. ( *(("(# ' {{
2.4 "# $$1 4,
J, *)+ "'("# DOT H3030("#
*) *,4""# Z *) + )1 # ,1(,(# Z ^H3(33--(-
"!
1-2 2 ( 2
(
H
# "'("# DOT
) 1 -
#
1 *
03$1
1*) + $
,("#
( /# 03
-
H Z
(
3.
!:5!&!
4
!*;:5!%
%' ,$/0
3.1
'0 3((!()*) +
(
,("!
-(("!
. ( " # $
1
. / (
3.2
-*) + 1
H
$1
$1
41(
(# $
#
" 0 ,
(3('
(, H
I 3V(
4 1
1
(
0("# V(*) )
DOT card (V(
*)( '4!4(V(*) )
3.5
'0 30*
((
*) + 34,
$"H
# 41
1,*)
$1-
56
3.6 '(,(
,
# (*) + *,(
3.7 )30
,
$ H)1
3.8 *) ((!(
*) + 03$1)1 V(
4 # 0
$4 # $1
,( 1
2
003
11$)0
(,
"#K("#3
4. &9 %
%' &&! F
4.1 ,
("# 011 Z 41(!(# -,(
, (DOT corner) "#
<1"
$3
0,3
<4
# -*) + 3 ("0# 3 DOT H". package
/1-
*) + 13( 13 ('*) +
,(.
0 (FDCs) H
# 0(""# 0# 3 DOT
'*)+ "#)1
(H$3
) *) + )1
H
(,
!-H 33
(
,("
0 DOT
"# (,
((. Z
)$1
H0, (*) + $,1- DOT 0
(,
(
-1
(
-"# (,
*,4"#
, , (K(
( 3)1
(*) +
"# ! 1 '(
("
"#
-)*
0 $
4.5 $1 1 *) + 03$
'($ DOT *)
,E
0V(*) + "# $1
)1(3 'J"#03 DOT 41(*)+ "# Smear-negative
003$13
"#03 DOT
1("#
*) + 03
(0
$
,(0, ^ 3
V("# -03003, , (
('"*# ) + $ $
,(*) + ,# , ,
,(
.
1(0("# (3V(
57
^H3
#,.(!
33--(3
#
5. &* : DOT
5.1 0" 3 1 "3(
03 *1(("
"3(*) +
3 DOT card ,"#
)1 ) (I 3
5.2 0)
3(3-)"#'J(*1(("
41(3 ,
(
3 *
03 {{ ( 3"(1!
2H
# "" (*
H"2
5.3 "' Cohort Analysis -*) + V(!(1 "-# (. "3(( 3 3
( H
# 3,(*
0
*) + ". 3*"E,-
!
5.4
H3
*)" "# '("# ((!(
(DOT Meeting)
observer H
# "IJ ! 3-((3(
, ,
58
% !
1. 13"<$"(H34)2 1
!,1
3" E!3! 44213"<$" : ( "
,(0, ^3
(3"<$" (H,H2. "#
2 ^!) H.<.2543
2. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of
America : Treatment of Tuberculosis AM J Respir Crit Care Med 2003; 67:603 ~ 662.
3. Fox W Ellard G A Mitchison D A : Studies on the treatment of tuberculosis undertaken by the British
Medical Research Council Tuberculosis Units, 1946 ~ 1986, with relevant subsequent publications,
Int J Tuberc Lung Dis 1999; 3(10) : S231 ~ S279 (supplement)
4. WHO : A Guide for Tuberculosis Treatment Supporters Document WHO/CDS/TB/ 2002.300 WHO Geneva
2002
5. WHO : An expanded DOTS framework for effective tuberculosis control Int J Tuberc Lung Dis 2002 ; 6 (5) :
378 ~ 388
6. WHO : Eight Report of WHO Expert Committee on Tuberculosis, 1964 Tech Rep Ser No. 290, WHO
Geneva 1964
7. WHO : Guideline for Establishing DOTS~Plus Project for the Management of Multidrug~Resistant Tuberculosis,
Document WHO/CDS/TB/2000.279 WHO Geneva 2000
8. WHO : Ninth Report of WHO Expert Committee on Tuberculosis, 1974 Tech Rep Ser No. 552, WHO
Geneva 1974
9. WHO : Treatment of Tuberculosis : Guidelines for National Programmes Document WHO/CDS/TB2002.313
WHO Geneva 2003
!"# $
$%&
'
( )*+
59
7.1 $%)
$$/0 0 &%)
) H,#
(
,4
. 1Z ". 4
. $1 (Susceptibility)
# *) , 4
.
"'
+ V( H,# -(. 0'( (*) + "# H,# -(. 03H1
304
. $
-(. ".
H1
304
.
((,
E!-) H,# 0'( (*) +
) H,#
(
,,
, , 3 1
23 "'
--
)-(.
)
-)-.(
0) 0'( (*) + 4 , 0
) 01
), !
(-*) , 4
. 4$ /*) + 2
-)
,(0, ^ (*) , 4
. 4$ /*) + 2
-(.
60
13 1
,4
. 4$ (*) +
13 5 '(,(
,0
(.
1.
.
$
3( 1
3 1*(( 32
1.1 0.2
3( 1
3 1*(( 32"!
3
1.2
%3 4!
-
,4
. 4$ (*) +
1.3 )
*(
'(,(( ! 32
1.4 '(,(
!
'
, 3,(*
,0
'(,(( ! 32
2. IJ- (
!1 *) , 4
. 4$ / *) + 2
2.1 , --(
(*) + (
!1 *) , 4
. 2
2.2
(
+ V( (*) , 4
. %
$$(3/,
2.3
(
H1
304
. ((,
3.
,4
. 4$ (*) +
3.1 ,
03
3
H
# ,(0, ^
,4
. 4$
3.2
)
# 2 3
(
,4
. 3H14
. 4$
3.3 $
/( (Co-trimoxazole)
(3
,4
. ^
3.4
-($ 2
3.5
)
3((!("0,0 3
1. * %$ $
$:$/0 &%)
2
3
$
3( 1
((23 (.( )1(H
.(K(-
333
'(,(((E!-(I00!( !32
$
1
(
61
2 &*EA
$/0 4' :5! & < <$/ :5*! $- &%)
2.1 &
&!
:5!*-$$/0 (Establish intensified tuberculosis casesfinding)
(
. :5! 9
!4 $& !
$/0
0
( (*) , 4
. 4$
$1 V(3(-,(
, )1 ()-0("# (2 0V(*) '
(Counselor) 0("#"#*,4(2
0("#"#*),4
.4$ )1( ) 0("#((
".
(('*),4
. *)"#03"'("#(
0
( $
H
#$"
H(E23 123
( "(
,(,0^3
(*),4
.4$
". ,E
(
0
3("
*
. !
$/0 4' :5! & <
+ V(
,-(. $"
! 33-2
". "# 3 CD4
1 200 //)
<
2, ,
#'
1 1
+ V( H,#
-(.
CD4
0.
0
, "!
6
(/# 03V(
33
0 CD4 "#
0"!
6
(41(
( 4
1
3 , #
( 1
(*(
)
"!
. ""# '
23
3
3,(*0'( (*),4
.4$ 1"."#$
0
30'( ("# 0H 1+
V( ".
,
(H
# 0
(.1$
"#
103V(
Suspected tuberculosis 1$1
K(HH(
,(0, ^ %3 3 0/.'(33 1-2
(
-)
1*),4
."!
(
"# H
# 0"("#"#
(
0
(."!
.
"# *) , 4
. H
((
/
-
62
Isoniazid
1*),4
. %H
#
(
!
+ V(
1("#03
Isoniazid (10 1*) , 4
. 4$ "# , 4
. 1 ((. $1$
'+ V( /#
0 ,(0, ^V(
# 'J
(
# 0
Isoniazid "# 4
(
V(-(((# (-(("# 4
+ V(
41(
(
+ V( $ ". *)" # $ 3"( Isoniazid 1
(,
$1#' + V( ((
. 1 Isoniazid ) "'
+ !1
-(.
(.(
(
+ V( Isoniazid 0$141
"#03'(,(
*),4
.
4$ "
! 1H0, V( Z 0-*) ,
3 H3<
H-(
,
E!-131
2.3 &4
!
*I$
' < $/0 4%"
%"&
H1
304
.
1*) , 4
. /*) + 2
!1 "# # 1
,4
. 2
0341
+ V( $
,(,0^3
*)+ 33H14
. V(
"# 'J
"#! ((H0!3(("# Z "# V()11 41( (
(0'
/# 0*) + 3*) , 4
. /*) + 2 1
()1
-
H1
304
. $(
4,
!
,4
. (TB infection control plan) "4# 0( ". (( (1)
,0
/# V(1 ("# 'J"# !
H
#
*14
. (2)
! 3 H
# --(- Droplet nuclei "# 4
.
3 (3)
4
#
(
((1331(
#
3. & &< <$4:5*! $- $/0 (Decrease burden of HIV/AIDS among TB)
3.1
,
#23,
03
H
# ,(,0^
,4
.4$ /#
'J
(
# 0
63
'J1
)*) +
! H 41(
($ 2(41 "# 3
,
#23,
03
,4
.4$ 0V(41"*)+ $
)3-
($ 2 ^H3(33
-
/# 41
4 , $
33 "# 3 "*# ) + $
04$ ( "
'(,(
(.
1. . 1*) + $
,(0, ^ 1+ V( -
"'"
2, 4
. 4$
-*) + 3
"# 3$ - H,0
*) + 003$1H"0# 3]I*
+ V( 3
,4
. 4$ (-3
( (
0
(. 0("*# )
)0
"(,
(
(
( (
"*# ) + 0H4
. (3
2.
#
2 2
# (. 1$ -
#
(
H14
. $0("# -H,0
-3
,"# * ) + 003$1$
1 80% 3
($
1*)+ "#,4
.4$
03
$ "'
!H4 . -(.
(.( (0((3($
1*)+ "#,4
.4$ "# CD4 #' "#!
"1"0# 3'(,(
$ 3*) , 4
. 4$ "# + V( (-3"
# '$ ($
$1 !
($
$H Z
($ ()3("")
3.5
0,
)1 (31(
# 1V( 2
3"# 'J
,
"#
!HIJ1 Z (Comprehensive care) 3
,
"# 1(
# (Continous care)
1.
)1 ( (Comprehensive care)
1.1 "
H"2/
H
1.2 "(0, ,"
1.3 "(<K
,0/
'4 , /,
"/
! ,"E,
64
2.
)11(
# (Continous care)
2.1
)
11*)+ 3 1(H 3
-1,
!-H3
(34!4(
2.2
"'
, 1(
#-
,0
1 Z (1341 -
'(,(-
,0
)1 ( 31(
# (41 "#
($ 2
( 1H1 *) , 4
. /*) +
2"#
,4
. -$
-(. ((3"#
. 1(,
!-H(133
^H3(1 ,
3K), (Primary care unit : PCU) H3V((,
E!-"#
4, ".
*) + 34!4("*# ) + <)1 3( ,( , ", # ('
,0
)1 ( 31(
#
$4$V(1"0# 3 H- 4!4( 33((
2
",(# H
#
*) , 4
. /*) + 2 3 $13,"E,H
7.3 4
!
* #, $<$%9
:5*! $- $/0 (Provide HIV testing and counseling)
4
!9* #,4:5*! $- $/0 & < <$
'
*) + "# $1 0
,4
. 4$
1(
1. *)'
33
4
. 0
*)+ ^H31,#("#H14
.$
($
(
1 2 2) ^3(.( "#3(
0V(
-(. 2 2 30H ,# *) + (
N 95
"#
1 H
#
H14
. ("# !
2. '
'J-
1*) +
- )
-4(, -(^H3("(# .'(
( "#
"'(3$
H1 3 ,E
(, (( 'J-
,("# 1 (
#
- -"
/(-
-
,(1#'H
# $1
,
.
11(
#
3. '
H
#
(
H14
. $)*1 ) (
#
$0
,(
)1 1
(
4. '
( 'J-
0
,4
. 4$ (*) + "# V( -3*34(2
"#$0
03" 3
,4
. -"#$1$
03 ,(,0^
,4
.4$ "#0"'
$1"1"# 31
#1
,^
#(
H14
.4$
1*)
#(
'
*) + "# 0H 1
,4
. 4$ 1
1. H
#
'03 -0 1". 34$ )
! H4 , 41(
(
,$ 3-
$1" # (I00!(
2. )
1*) +
'(,(3
,4
. 4$
3,(H3
33-2
3,(",(,
3
03),!
(*)+ "!
($
0 CD4
H
# "33-3 *(
"#
) ("# ) , !
((
1 200 /2/)
<
2, ,
$
( PCP 3,#
($
, -.%$%$
!"# .$/
65
3. '
#
4($ -(- ,E
(, "#
) -"
/(-
0,11(
#H
#
(
3
,4
.
. ".-)
-
($ ,"E,
3
(!-H33
( H
#*)+ )
,"E, 3) 1
H
#
4. '
#
)!-((1)
"(
'
(, 1
,(3
0,0
H"2 (( 1V(
4 , 3*-
-
"'
14 , $
'
*( 3
! ( "# 330
(
0
,(
. 2
*(
! V(,# ""# '$
320(4
. $ 2(1
(
1 50 5/ )
<
2.
5.
'
#
1 H<1
1! ("!
. "#
1 H<H
#
(
4
. 0
*) (
#
H1
30-4
. $)*1 ) (
#
,0
3
4-^1
*) (
#
1 300350 cells/L
",(,
-
$1
10
(*)$1,4
.4$
1
HH"2
-
# ! 01
$1H1(.'
1
2. *) , 4
. 4$ "# 3), !
(
H1 ^H31,# 3
- CD4 (
1
200 cells/L 03H (
H1
30$
13 50 ("
1. )"#4
(*),4
.4$ $1
10
"# $ (3('4
)K(33(. 6
( (1$
*) 4# 4J"1((3('V( 9
()
2.
H,0($ (*) + "# , 4
. 4$
, , (.
2.1 H,0,# ($
# 3
- CD4 (
1 250 cells/L (TB treatment before
start ART)
66
, -.%$%$
!"# .$/
67
% !
1. Self-study modules on tuberculosis, US-Center for Disease Control and Prevention, p 19, March 1995
2. Interim Policy on Collaborative TB/HIV Activities, World Health Organization 2004
3. Mohammed, R. Ehrlich, R. Wood, F. Cilliers, G. Maartens, Screening for tuberculosis in adults with
advanced HIV infection prior to preventive therapy, INT J TUBERC LUNG DIS 8(6):792-795
4. Kimerling M. E.1; Schuchter J.2; Chanthol E.3; Kunthy T.4; Stuer F.3; Glaziou P.5; Ee O.6 Prevalence
of pulmonary tuberculosis among HIV-infected persons in a home care program in Phnom Penh,
Cambodia INT J TUBERC LUNG DIS 6(11): 988-994 November 2002 IUATLD
5. ( "34,: !"E<2
**(
'(,(( 32 H
#
!3
(
(*) , 4
. 2(3"<$"
3" E!- 2544 ISBN: 974-294-006-1
6. ( "
( ((,
E!- 3"# - 0'
""H
, 2
(
2003
!
3" E!7. WHO. 2004. Guidelines for HIV Surveillance among Tuberculosis Patients, second edition.
8.
!1 '(
2 3,1"H<H(E2.2550. )1
(
0
H
# ,(0, ^
,4
. 4$ (,(
, . '(
H,H2
]]_(2$ /(2.
9.
*H1
!1 '(
2 3,1"H<H(E2. 2550
)
K(
The Tuberculosis Coalition for Technical Assistance.
10. WHO Geneva. 2004. A guide to monitoring and evaluation for collaborative TBHIV activities
11. )(,E , 0, 32. 2549. 04$ H
# 4 , H
# *) + "!
(.Orane group 086 924
3434.
12. World Health Organization. Strategic framework to decrease the burden of TB/HIV.
13. WHO/CDS/TB/2002.296. Geneva, Switzerland: WHO, 2002.
14. World Health Organization. Management of TB: Training for health facility (A: Introduction). WHO/CDS/
TB/2003.314a. Geneva, Switzerland: WHO, 2003.
15. World Health Organization. Guidelines for HIV surveillance among tuberculosis patients, Second edition.
WHO/HTM/TB/2004.339. Geneva, Switzerland: WHO, 2004.
16. World Health Organization. WHO report 2007: Global tuberculosis control surveillance, planning, financing. WHO/HTM/TB/2007.376. Geneva, Switzerland: WHO, 2007.
17.
,
"
H"2
4"2. (*
*) + (
(0'/"( 8 1(-
68
0
1
( "2
69
8.2 &*EA
$%9A &
4* (
0
WHO/IUATLD Global Project on Drug Resistance Surveillance /# ' 0
. (
3
Population-based ( 58 3"<3 1 1996 3 1999 H
. MDR-TB (*)+ 1 (primary)
1) 3 1 0% 14.1% 3H 1(
' 0. "# 2 ((. 0'( (-H
(. ""# #
. 4(, MDR-TB
) (Hot spots) H,#
-(.
1
' 0. "# 1
(
2
. (3"<$" 0
-)
' 0
. (41 5 H.<.2540-2541
3 H.<.2544-2545 H 1
. MDR-TB (*)+ 1 "1
2.02% 3 0.93% '
'*)+ "#
1( H
.-((V( 20.3% 3(
' 01!."# 3
#
H.<.2548-2549
. MDR (*) + 1"1
1.65% -3"#
. -(((*) + "#
1("1
34.54%
(H
(. "# 13(34
1! 03H
. 4(, primary ". # Z (and drug
resistant) 3 MDR-TB )
1(
1! 34
" # $ 41( (
(0'H MDR-TB (*) + "$# 1
1() 5.9% (
1! *) , 4
. 4$ "#
+ V(
H MDR-TB ) 41( (("
5
2539 H 8.8% 30 4 18% -38% 3((H (hospital-based) 1 41( H
<(,("2 -(
1( 3HE, H 1 MDR-TB (*) + "$# 1$
1(
". "# , 4
. 4$ 3$1, 4
. ) 5.7% 3 5.1% ' 4!
-
. MDR-TB (*) +
1(H
(. "#
'(,(
DOTS-Plus '(,(
(H
(. "# Z
! 1) (
# 0
0'V(
"0# 34"H
3 1
(,
"
H"23E!-1
(Z 3H
#
4
# (# "' DOT -3"#
4 second line 11(
# V(33 (( (
0
(. 0'V("#
03H[(
-13
H34
. 33-)"#H
#
,323('$H[(3
)
,# -(.
8.3
!
:!*5 $- % %$ & $/0
70
0"
/("'4 ,$ 3
H14
.
.($ (.(
1 13
0",
, ( "# 3 0341
,(0, ^
. $ 3
"# 3
$"(
8.3.1 *)+ "#
. -((
*) + "#
)"0# 3 3
. -(( $
1
1. *) + "#
. -((
1(
*) + "# , 4
. 4$
*) + "# 3
, *
*) + MDR-TB ( ". !
"
H"2"# + V(
33
, *
*) + MDR-TB)
1! #
(# Z 41( : *) + ( 4( *) + (
(0' (, *H-(J1
2. *)+ "#
. -((3 1
*) +
'
) CAT1
CAT2
$1- (. 1
3$1# (
V(
# ,(. !
33--( 30
4 4 4(, 1
1
(3
1)
*) +
'
) CAT 1
CAT 2 *
3H"2*)
(# 0 1*) + 3"(#' ^H3$
,E DOT
1! (.
# "# ) 03V( MDR-TB
*) + "-#
,( 2
( ,1
(
0/.' 3*3V(
0
1
( "2
71
# H*) + "#
"0# 3
. -(( , , (.
1. 13H
# "' DST
H
(. K( 4 - 5 4(,
H R S E 3 Z
2. 3 1* DST
)
. (1$ ( "(.
2.1 H,0# (3V(3( "# 2 $ (*) + "# 1 CAT 1
CAT 2
3 Empiric CAT 4 (1)
Empiric CAT 4 (2) '
2.2 3,/#
'$ 1-) 3((. $
1(3* DST (,# "# '( :
*) + 04
. 4(, Nontuberculous mycobacteria (NTM)
$)
/
$ !
$ ,&!$
CAT 1 4$:5*! $-
*
%9%&!$
DOT /
' +$ * 4<!
CAT 2 : ,
&9
"! * $ <& *;*&! & &
!$ (Acquired MDR)
*;
Sensitive bacilli 5 \ &! 4
! : DST "! :5*! $- & + % $$ *A
E
&< HIV
&!$ 4
!* #,):5! < $<A*; / F * \& $) 0
94
!4<! CAT2
:5*! $- 9 ,&!$ CAT1 : $%
% & 5 *;
$ W# 4<! CAT4(1)
4
! HR * : DST
4
! CAT2 4
! /*; F
72
(
H,03"#034
8.4 #
,:5*! $- MDR-TB
-(. "3(*) + MDR-TB $V( 7
!1
0
3"3(
, (TB 03) (.
1. New Category4 patients : $
1 *) + "$# 1
(
1 (less than)
1
( (
"# 1 3 0" $ -4
. 1 (DST)
# ,# (
3
CAT 1 31* DST 1V( MDR ( ,E Solid media method 03"* 3 - 4
(
1)
0 *) + V( New Category 4 patients 1 03$ CAT 1
,(
1 1
(
2. Relapse Category4 patients : $
1 *) + "#
3 1
V(/.'*
DST (-3"# 1 0
1(
/.') 1V( MDR
3. After Default Category4 patients : $
1 *) + "#
- > 2
(,1
1(
. * DST (-3"# 1 0
1(
. (). 1V( MDR
4. After failure of first treatment : $
1 *) + "#
.
(1 (J1 3 CAT 1)
(*3
#
("# 5
) * DST (-3"# 1 0
# ,(.
("# 2
5)
1V( MDR
5. After failure of retreatment : $
1 *) + "#
3 CAT 2 (*3
#
("# 5
) * DST (-3"# 1 0
# ,(.
("# 3
5) 1V( MDR
6. Transfer in : *) + CAT4 "#
) 11 (Transfer) 0
(1 ,
(# (/# $-(. "3(*) +
CAT 4 ) $
(1 ,
(# H
#
1 (*. ) + 0V(*) + -(1 ,
(1 ,
V(*))1(
#
#
031*
$(1 ,
7. Other : *) +
(# Z "$# 10-(
!1 1-6 3 *) +
CAT4 "$#
0
(1 ((
3 NTP ($1-(. "3(*) + 3 NTP)
0
%"
,:5*! $- $/0 & $ !)*
&$
% "* %
$ F $! 4
! ,* %:%5
% &' : *5! $- #&!
4 / &)*
&$* $% " ,:5*! $- $/0
& $
&!& $ %:5*! $- * ,4%"
$ !
4 ,
:5!*-$&*
0
1
( "2
73
8.5 $/0 $ 1 2 4 <!4 ,:!*5 $- $/0 % %
&
&$
1 ( "# 1 3 2 "# 4(
*) + "# /
. -((3
-(1 (
:!5*-$9
$ :!5*-$9
$ :!5*-$9
$
!$ 40 40-49 0 4<! 50 0
$,
0 4<!& & ( ) / # *4<!&
( ) /$
$
( ) /$
750
1000
Kanamycin (15 mg/kg/day)
K
500
^-
(3 1 .
1,200
E
800
1,000
Ethambutol (15 - 25 mg/kg/day)
2,000
1,000
1,500
Z
Pyrazinamide (20-30 mg/kg/
(27)
day) ( 3 1 . (
3 500 ,,
)
600
800
400
Ofloxacin (7.5-15mg/k/day)(18)
O
3 100, 200, 300 ,,
( 3 1 . *
500
500
750
Ethionamide (10-20 mg/kg/
Et
day)(18) 3 250 ,,
1 ( 3 2-3 . **
500
750
500
Cycloserine (10-20 mg/kg/
Cs
(18)
day) 3 250 ,,
1 ( 3 2-3 .
8000
10000
12000
Para-Amino Salicylic acid
P
(200 mg/kg/day) 1 ( 3 2
(8 gm.)
(10 gm.)
(12 gm.)
. (3 1000 ,,
)
500
750
1000
Streptomycin (15mg/kg/day)
S
^-
(31.
750
1000
Amikacin (15 mg/kg/day) ^
A
500
-
(3 1 .
': * ( 3. 0(
103*-
011 ( 3 2 .
**
31ZH,# -( 41( ,# "# 500 / (
1( 1-2 2
# 3,( 1"($0 H,# V(-(
,
74
8.6
4 <!4 ,:!*5 $- 0 %%5 & & <& MDR-TB
*) + "#
)"0# 3V( MDR-TB 1 (J1 $1 0'V(# (3"(" *
DST
((
1( 1
V($$) "0# 3V( MDR-TB 3
*) + 1(-(
(seriously ill)
# ($43 Empiric CAT 4
1((3 1"# * DST
4
*) + MDR
Suspect MDR 034"# 14
. $1
. 4 -(( V(^ 1 -(( 3^ 6
(
3 Empiric CAT 4 2 3$
1
1. 3 Empiric CAT 4(1)
6 K5 O. P.E.Z / 12-18.O.P.E.Z
4'*) + "
# '
3 CAT 1 3*
V( Failure 3 1* DST
1 4 . 1
,
. -(() (# 0 1*) + $1$ S
1(
* DST "# 1
-3"# ,# CAT 4(1) 4
. $ 1 S S "( K
(#
3,( 1*) + Failure 0
CAT1 3
"# 4
. 03
. 1". E, Z
0H,0-$4) CAT4(2)
2. 3 Empiric CAT 4(2)
K5**. O. (P*). Et, Cs.(Z) /12-18 O. (P*). Et. Cs (Z)
* 0
PAS(P)
Ethionamide(Et)1 0'V(0H,04". 2 -((
** (
-^ ^"!
( (
1(23 5 ( ) V( 6
( 1 *
03 ,E 4
. V( 0H,0^V(23 3 ( ( ( ( () V(
3
(
(
0
(. H,0
,("
# '4 1 3,"E,HH 3*) + "("E,- -^$$
1 * 03H4
.
# ,(. !
("# 3
4^(( 6
(
0'V(
4
^ (("# ! 1( 6
( *) + "($3$1
,"E,- "# (! 0
(
"*# 03V(. 1
("# 2
3 3*) + "(^$11 $ 0H,0
^0
23 5 - V(23 3 - ( ( ( ()
,&!$
$ 2 Empiric CAT 4(1) Empiric CAT 4(2) 9*;!4
!
,&!$
DOT '/+ 0&!4
!!
!% /%'
%% % /%'
:
* %
/)*;
,$/0 *& *; MDR-TB
(
H
( ,# "# '(
"# V( (
)"1 # 3
3"1 (
(Central Nervous System) "#
4
! , *1(
# ! , $-($
RMP, INH, PZA, Pt, Et 3 Cs /*1($- 3"# Kanamycin, Amikacin, Capreomycin
/*1($ (-3"#
# !
1 ( PAS 3 EMB /*1($(
75
,*
1(
0",
, (.
7.7.1 &: , ()"# 2 3
)
,*
1(
0",
, (.
03 Direct smear 3
H34
.
# ,(. !
("# 2, 3, 4, 5, 6
0
((. "!
3
( 0(
".
0
# ,(. !
0
" $ 1(
0'V((
1H 0(
("# 3
("# 6 0
((. "!
6
( 3
# ,(. !
2
0",
, "0# 'V( H
# ,*
(-
End of Month
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Direct smear
Culture
Sensitivity
CXR
76
1 (J1-*)+ "#(1
3*
03
#(-3
0
V( ( 6
(
-
0(*) + "($1$
5. Defaulted : *) + 3 CAT4 "-# > 2
(,1
(
6. Transferred Out : *) + 3 CAT4 "#
) (
$
1"# (
# 3$1"*
8.9 &
,
H
#
, Relapse rate Direct smear/Culture V( 24
(
( 0
"!
3
( ( 6
(
30
((. 0/.'"!
6
( 0( 2 5 '
1HH0,
0
# - 14.
8.10
&
:5! % :%
:5*! $- MDR-TB
*) *
4, (Close contact) *)" # <)1 ((
*) + MDR,
4 1
*) +
(34 # (, (""# "# '((Z (Indoor living space)
'*) J1"# *3
$
3,( 1
'+ V(
$1 V(
H,013 0 DST "(" -3"# * DST
Empirical regimen $1V(
,4 (3"# 3 ($1 4
!1 Quinolone) 0H,0"' CT scan
Bronchoscope 0'V(
"# *3
+ V( MDR-TB *
4,
MDR-TB
*
4,
77
(
"#
K( 1
,4
. 03'( 1
,4
.(.(Z0$141
,0
*) +
.
4. -)33,(*3
'(,(( 3*
(33"<
5. -)
%3
.33"<
)
%9*I$
'0 $
'0
1.
1""( 1"( "
)
*) + "#
. "# V(K(
-3"< 3( "
(3 !
H1
304
. ((H
2. H[(<
H!
1(1 ("#
# -(H
(. "# *,4
3. ((!(3'
H
#
0.
-130 3
'(,(((
3
-1"# 3,"E,H (
((!(
H34
. (H."# H
(H
(. ""# # J
I
. )
4. 1
*) 4# 4J (
'
#
,(0, ^ )
*) + "# J
I
.
1H(H
.("#*,4
5. (,"<(H1-1(H
.("#*,4
6. -)33,(*3
'(,(( 3*
(H
.("#*,4
78
7. -)
%3
.(H
.("#*,4
8. ((!((H(H
(. "# (
0. V(1-1
,(0, ^ )
*) +
.
(Specialized MDR-TB Center)
/Y)4 & Specialized MDR-TB Center
/Y)4 & Specialized MDR-TB Center # 40
%"
&9&5 ,:5*! $- $/0 & &!$
$/0 $% %"
0
$ $ ! & :
1. &!
:5
!
"#$%9A*EA
2.
' )% /%' 4 4
! &5:5*! $-
3. &! <%5 %:5*! $- &
4.
DOT 4 ,:5*! $- $/0 &!$$/0 $ 1 &
5.
# :$/0 &
6. Second line /
' +
3"
/("# V(!(
1*) + (H
(. "-# 0 ((. Z
H
(. "-#
-1((. Z (
"$#
1
6. , 42 ( "# ( "- 4.
)
$4
! ,:5*! $- $/0 & 4%"
(MDR-TB clinic)
41( (H4!4("# V(), '(-*) +
1.
(*) + "#
. 1 0H
#
((
,(0, ^
.
2.
*) + "# 1 10
.H. 1-1 (Specialized MDR-TB Center) 3
"$#
'( ,E
(Directly Observed Treatment) !
"
H"23E! ".
,*
( "14,'
.-((
0
1
( "2
79
3.
*) + Ambulatory ,E Directly Observed Treatment ((!
"
H"23E!4.
%3 )
*-0
"#$1!( 311*)+ H
#
1H1-1 (
"#V(!(<
H-(H
5. 3,(*
-*)+ (H
.("#"#*,4 1
H1-1
6.
#( Z 41( (*)* !3
(
H1
304
.
.((
H
)
!
! $/0 (H1-1 3(H4!4(
""(
)*) + "$# 1
.
1. 03,(
, *) +
.
2. 3((
!H"2(H1-1
H"2 (H4!4( (
( "# 2
3. 0"'3
-(. "3(*) +
. (Registration)
4. %3 3
)
- 31 03H
#
,*
31 3,(*
5. 1 3,(*
*) 3(( 30 (PTC) 3H"2 H *)
(
"#,(, (.()1((H1-1 3(*
1'(
(E!-0
H
# 3(1$ .
6. 3((
*) 3(( 3'330 (
0"'(
7. 1 (
03 !3
(
H1
304
.
.((H
[)
:5*! %$/0 &
9+
""(
)*) + "$# 1
. 41( 1 (
0"'"3(*) +
.
(Registration) 3,(*
*) + (- *,4 3
0"'(
<)
:5*! %$/0 &
$&
""(
)*) + "$# 1
. 41( 1 (
0"'"3(*) +
.
(Registration) 1 *
(*
(*) +
. 1 3,(*
H
# 3(
1$'(
(E!-0
W)
:5*! %$/0 &
""(
)*)+ "#$1
.
"'"3(*)+
.
(Registration) *
( *
0
*) 3(( 30 H
#
3,(*
'(,((
(H --1$
x)
!
!4%"
1. 1 (
*) + Directly Observed Treatment
2.
H 3'(3(' ".
11H
#
((H"#
3
80
0
1
( "2
81
% !
1. Siriarayapon P, Yanai H, Glynn J R, Yanpaisarn S, Uthaivoravit W. The evolving epidemiology of HIV
infection and tuberculosis in Northern Thailand. J AIDS 2002; 3: 80-89.
2.
!1(,,
4(),
!1 (2547).
('((
34!!*(30'5
!1
5 2547
3
3. Yoshiyama, Takashi. Supawitkul, Somsak. Kunyanone, Naowarat et al. Prevalence of drug-resistant
tuberculosis in an HIV endemic area in northern Thailand Int J Tuberc & Lung Disease 2001; 5:
32-39.
4. Annelies Van Rie, Robin Warren, Madalene Richardson et al. Classification of drug-resistant tuberculosis
in an epidemic area. Lancet 2000; 356: 22-25.
5. Iseman MD. Management of multidrug-resistant tuberculosis. Chemotherapy 1999; 45(suppl 2): 3-11.
6. GUIDELINES FOR ESTABLISHING DOTS-PLUS PILOT PROJECTS FOR THE MANAGMENT OF
MULTIDRUG RESISTANT TUBERCULOSIS (MDR-TB). Geneva, WHO, 2000. WHO/CDS/TB/
2000.279
7. Payanandana V, et al. Surveillance for antituberculosis drug resistance in Thailand: Results from a nation
survey. Thai J Tuberc Chest Dis 2000; 21:1-8.
8. Pablos-Mendez A, et al. Global surveillance for antituberculosis drug resistance. N Engl J Med 1998; 338:
1641-1649.
9. ANTI - TUBERCULOSIS DRUG RESISTANCE IN THE WORLD Third Global Report The WHO/IUATLD
Global Project on Anti -Tuberculosis Drug Resistance Surveillance 1999-2002. Geneva
10. National Surveys-cluster sampling proportional to size, TB Cluster, Bureau of AIDS, TB & STIs
3
11. Amatayakul N. MDR-TB in hospital-based. Thai J Tuberc Chest Dis 1998; 19:73-80
12. TB/HIV Research Project, RIT-JATA
3
13. Reechaipichitkul W. Multidrug-resistant tuberculosis at Srinagarind Hospital, Khon Kaen, Thailand. Southeast Asian J Trop Med Public Health. 2002 Sep; 33(3): 570-4.
14. ![, ) ![, 33
.( (*)+ ,4
.4$ 1
-H
E, 5 H.<. 2543-2544 "
3 4' ,
, , 2546; 24: 221-228
15. Suarez PG, Floyd K, Portocarrero J, Alarcon E, et al. Feasibility and cost-effectiveness of standardised
second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru.
Lancet. 2002 Jun 8; 359(9322): 1980-9.
16. Pleumpanupat W, Jittimanee S, Akarasewi P, et al. Resistance to anti-tuberculosis drugs among smearpositive cases in Thai prisons 2 years after the implementation of the DOTS strategy. Int J Tuberc
Lung Dis 2003; 7: 472-477.
17. Crofton J, Chaulet P, Maher D. Guidelines for the management of drug-resistant tubercusis. Geneva,
World Health Organization, 1997
82
0
1
( "2
83
(Tuberculosis in Children)
!"# $% & #
&!
'&(
)(*
$
'*%+ ,
*-
$(
.
&!
)(
)&
*-
"+ &&!%#
'
$"+
!"# $%
*- ! )
$
/&&
.' '%#&)
"#& '%+$%*'01& )( *$
$
$ #2
("&
'%+3# *
$ $ )(! $%&)( (cavity)
3/ #
*-
'
3 3&7
83&*!
$$
!"# 3& !7$!
!"#
$ 9/&+ )&:/&*'013&
7$'%+ &**7&
.
# !) '&
%
! ethambutol &&3
$
20 $((
$/
(
$/
>'03? &
%&'%$+ % ( #
1)
'&(
* ,
'%$+ %
)(
)&
3
$
3" + %
& 2 3)
1.1 1&%'&
(
.$*
'
%+ 3
$%* )&# ) $ #2
("
'%+3# *&
% "$%)(
"# *$ "$% #2 !&
"+ 7$ * "
*- ! miliary B(B
:1&%'&
'#& )( 3&
"+
'%+)$ 2$
3/#
1.2 *C
'7
8(7 10 $$. $
%9% %9% $% )("$
$ &!%:# &/
!"# M.tuberculosis 9/+&$%$2
*
$
)(
. ('%+$%1$7$
&"
!"#
!% !3 5 $$. :*C
3 '7
8(7 15 $$. 7 $
:/&)$$$%
*6
%+ &
$)
84
$
"+
!"#
$%$
$
!"# $) 2'2
0% $J '&&*C
!
)
") %# 0'% &9%(%+
'! &J $% $)($2
(
%&
0% $%'
(AFB stain) /&&$ $
!'+* *67
0% !%''%+ $!
$
"0% PCR
"+&
$%$
(
"+ 7$ $& $%
)&3&$ $&& (increased intracranial pressure
! *H%.$
%
85
!
%
*- )$ "
(%# &
9/&+ &:
&)($+2
$ * &
86
&J%3 /#
( 1-2 *8 ( 80
%!
3
" )(( 90 %3 /# $
4
" 1&%*'%$+ %
"# * !
( 10 - 12
" /& & #
$"+
. 6
" )(
:&
1&%* $2
*- &
# 2$ #2
("&'%3+ # *!
( 2 - 3 *{
/&7
*- *
& # /&$2
*- &:1&%*J
3&
%&3& $
$%(" +
% $(
*-
!+ )( J * :$%
7 )&
!
*- 3 *3 %9 &7)(
9$8
3&
.$$
$$ "*/
.
!%+ !
$"+
) &J * /&
$+
.
3 J
.*
(%$
( 95 Relapse
( 1
*|&
'%+ '% %+ 7 "
* , *
!
$$%
!"# )(
.
&:
&
"+ $)
!"# *
$%
1$ $7
%9% %9% %
"+ *|&
$
* , # $%*! 8
$ '%
+ %+ &
*- J *
1.
%9% %9%%(
*|&
)*'01&$
*- '%+
8
& '+ (
1,200 & 7*9% %9% % $:*|&
1$
%&(
50 *|&
"+ 7$ $& ( 64 )(*|&
! )
( 78 /&'2$% $$
(9% *|&
! $'$%+ *% '01&3/ # $:*|&
'&# primary, reactivation )(
exogenous TB $%
' (%$J
!
(9%
cell wall antigen ! recombinant technology 9/&+
&
H/
.'&# #
*
'H'% 9% %9% % )
)
*67 %# (7$
)
(
" ( 100
%
7 $$*% ! 8
$$:*|&
)
'%)+ $
!"#
!% "
'%+
!"#
!%)$$%
$:%9% %9% %
*C
3&
%&(&
%9% $)
&
*
!
9% %9% % #
%# !
!"#
7 10-14 *{
*-
2
*67 ) 2% 9% *
'H'%$+ % high prevalence 3& (&
40/100,000 *{) *
'H'
.H. 2535 $%$!7
'
83/100,000 *{ )( .H. 2549 $%$!7
'
62/100,000
2.
!
"# (Treatment of Latent Tuberculosis)
'%+
!"#
$
'
%+ *- * (
&&+ !
$$
!"# )
)(
&$*,
*- 3/ # $ :"
)]& (LTBI) &*' *|&
"+ $
!"#
( %#2
* *,
*- 3/# $ :"$%$2)(
*- /+&3&
(7'08
(& (TB Elimination)
!
87
7
1 *{
$"+
!"# *,
*- 3/ # $( 40 - 50 !& 2 *{)
'%+
!"#
)($%
*,
*- ! 7 )&
$%
( 10 - 15 3'%+
!"# $%
*-
( 5-10 !&(!%
!"#
'*C
'7
8(7 '%+
H 8
(& 15 $$.
$$%
1:&%'&
*
H/
.3&
& 2 &#
$"+ .H. 2538-2540 )( 2542-2543
7
5 *{ '%
+ %9% %9% $% )(&# ))
$
*
&'%*+ ,
*- *
!
$
!"#
*,
*- ( 9.1 )( 8.2 $(2 *~
'7
8(7 15 $$. (
22.6 )( 18.7 $(2
"+ &
H/
.'&# 2 &#
*-
H/
.) (& (retrospective) /&
H/
.
) prospective
$"+ .H. 2547-2549 $%
*,
*- ( 1.64
!"#( 61.4
H/
.
&*
'H
*,
*- *$( 1 )(
!"# ( 20-30
( %#
*' *|&
&# )
!"# (LTBI) )(*' *|&
:&/
( 90 )($
*- ! )
*:/& 19 *{
*' *|&
$%*! 8$
!"#
*- recent infection
$ )(
$
7 )&
!
"+ 7$ $&
! )
" !$%
2.1)
$
* , *!
$$
!"# (Infectious Index) )'8'%+ * ,
) 2
'7
$
$7 )'8
$% :7*&8
*- "
!"#
"$ (3
%
# %
Contact Investigation) 9
*
*, &
:1&%*
)('2
'*C
'7
87( )
'%+$$
:)(
*- '2
.$
:)(
$
*-
*- 1
!"# *' *|&
& %#
- 7 < 5 *{ '7
*' 9 9 5 - 10 $
./ 6 - 9
" ($
*C
'7
8(7 $%3
')
- 7 5 *{ '%*+ C
'7
8(7 15 $$. *' 9 9 3 5-10 $
./
./ 6 - 9
" :*C
'7
8(7 10 - 14 $$.
. LTBI
*- J * :*C
'7
8(7 < 10 $$.
]|&
*,'%
+ 3
:$%$ : '%+ $:$
88
$
*' $+2
$ '%+
!"#! "# isoniazid
$
rifampicin 3
" " rifampicin 6
" " */
.
!%+ ! " $
:$%
*,$
*' $(
5 !
" #$%!&' &$ &$(
)* )+& ,
#!
" %!&'
$
(-." " 2.1 *
-#+ 0
2.2
*|&
(7$
%+ &" + 9/&+ $$*% $ * ,
*- 3'%+ 3 3&
(7'08
(& (TB Elimination) )
*' 9 9 6 - 9
"
< 5 *{ '%*+ C
'7
8(7 15 $$. (
'%'+
%+ %9% %9% )%
'%+1$7$
+2
!
*- 1'71!
,
*- '%+
2(&*' Steroid,
!"#
89
'
1.
% 7& '8, 2
', 7! $H
'%+
)
!"# )(
'&
2526;4:7-14.
2. Srinavin S, Chotipitayasumondh T, Suwanjutha S. et al. BCG Efficacy, Pediatric Infect Dis J 1991;10:359-65.
3. 718 73
8, H%*1
$.
(
$. )('&
2542;2:
10-8
4. Guidelines for the Investigation of Contacts of Persons with Infections Tuberculosis : Recommendation
from the National Tuberculosis Controller Association and CDC MHMR 2005
5. International Standard for Tuberculosis Care (ISTC), stop TB strategy and Global Plan to stop TB http://
www.int/tb/publications/2006/istc.report.pdf
6. American Academy of Pediatrics / Committee on Infectious Diseases. Tuberculosis. In : Pickering LK, ed
2000 red book : report of the Committee on Infectious Diseases. 25th ed. Elk grove Village, Il :
American Academy of Pediatrics 2000:595-611.
90
91
!"# $% 3
1.
2.
7$1)($
3.
7$*|&
7(
1
(Administrative control)
:"
*- )
3&$
7$
)
!"# )(
*- $
'%+ 2'%+ 7
7*&83&$
%
#
"+ *|&
$
expose 7(
)(* , " + J )((
)
!"#
'%+$%
&)(
.*,
'%+7
'%+ % *
1.1
*
$ $
%+ &
)
!"# :/&&+ * %#
2 * , )(*{3&:
)(3& &
! )
7
$
3&/
* ,
2 #&3&
*, )()
'%$+ % $
%+ &&
)
!"#
! '%
+
$
1.2
&) &#
$
"+ !
2
& )(&)
$
92
&"+ 3
()(&*$$'#&
*
$ 7(
1.3
$7(
073'%*+ C &
"+
3:/&
7$
)
'%+
%$2* ,
&&+ * ,
$
'%+
/ * ,
:$%* , '%+
"# &
2 - 3 *8 9/&+ &
*- :$
$:)
*,"+
&
"+($
%+& '%+7(
)(*,"+ J
$
1.7
(
$
!"# &! :/&&+ * %#
2
7('%
+
%+ 3&
' # '%+
3* &!
'%+ * ,
$ $ &!
$%!& &
&&
$'%+
$$
"#
$%&!!
'
93
*-
7$1)($*H
!"#
H9/&+ $%0
% (& (
&&$2
*- &!
' (%'%+ &7
99 )($2
*- &
%! $
)0
% &&
'%+ &!
' (%! # &
$2&(3 '$%+
%
)(
.* , 2 $
)(
&$%&*$
%& & # /&
("
0'% %+ 2
*- )(
$$
:
)()&
0
% &J $%& * %#
1.
:
'
H$0$!
*- 0%'%+&'%+7)(
%! '%+7 H
(
:
'
H
'%$+ % * , "3&'&
& J
! $%
:
'
H
'& &1
: '%+ '%+$%$
%+&
)
!"#
! TB Clinic " TB Ward
/&$% &'%+
H1 $::
'
H1
)($$%
"+&*
H 9/+&
*- 7*
:
'
H1
:&$% &
%$%
)(
*(%+
H
*$
(
!& # J '%+
( &
' # & # /&$% &"!&'%
+ * ( 3&&
(
*- & 2 " &
*)
2.
!*7
8
H
! $% ($
H'%+ & "!*7
8
H
1
"+
$
H
*- ( (Negative pressure) *|&
H'%*+
*
!"#
3$
"
J
2 'H'&3&($$%$2
"+
H'%$+
% !"# *
* :
&
" + J
2 'H'& &2 /&:/&
H'%+7'0?
7(
'%+*C& *&*,)(
1
'%+
*- '&
33&
H &
'%+
H
"+(%
(%+&
(
(3&
H '%*+
*
!"#
3.
!7*
8'%+$%
' (%7&
99 )(&
%!$
)
&
H
"+
Particles '%$+
% !"#
*
%
High-Efficiency Particulate Air (HEPA) filter "
!"# )&
7(
( (Ultraviolet Germicidal IrradiationUVGI)
*-
"+ &
&
H 2
H'%$+
% !"# *
*
3*
"+ &
& 3
'2(
94
-"'8%=
%!>
-/0 (UVGI)
H/
.
!"#
$"+ :
)&7(
('% +
%& /& 2$!
'2(
"+'71&$+2
$ /&$%*'011
%&
'2(
!"# :
073
3
8&
8
*|&
!"#
7(
*-
%&$
$
7$
)(
7$1)($ & # $2)(*'013&
*|&
7( 3&+2
$"+
*%
'%
$
" + J )(
*-
*|&
!"# 7' 9/&+ *! 8
7(
' #
!*7
8&&/&) 2! : '%'+ $%+ % $
%+ &
!"# &
! &)
3&* ,
(
J 3 1 $
! HEPA mask, N.95 9/&+ ) 2!
7(
& Bronchoscopy "& Lab
'%+ &
!"#
#
%
-/0 "6
7 8
'9'8*
7(
'&
)'8
*- '%+$%$
%+&
!"#
H&
*C& 9/+&&$%
*|&
&
1. $%$
%+
(
.
)
!"# )() '&
*|&
2. 7(
'%
+ 2(&
$+ '2&
!&
*- "$ :*
% &
95
'
1. $ &H8
&%+$ )('%'&
(. ) '&*|&
!"# 7(
'&
)'83&
&()(:
'&
)'8'+ *. )('&
.2539 ; 17 : 131-136.
2. World Health Organization. Guidelines for the Prevention of tuberculosis in Health Care Facilities in Re
source-Limited Settings, 1999.
3. Centers of Disease Control and Prevention (CDC). Tuberculois Infection Control in the Era of Expandin
HIV Care and Treatment, 2006.
96
11.1
11.2
11.3
11.1
!"#$%&'
"
!
)*
$ .+ ,
*-$%&
#"$
&$/ & % /
0
%&
'0 $%&#/45+6
# %**7+& $
-$'0
$
- 706+8# 9:& 60 ;
'
#"6
0 '6$!"#
& 60;
-
$%&'
6$*'< $
#
60 ;
% '0:- =
- !"#
: %6$6
#+
#!"#
> >
> %'+$?+@* $
#-
$%&-#*>
>
%'7+'?'$
- @
5 0 +$% & % 0 +
%"
! #0
#+0
460 ; % ## $
4> >
5%
%$
-
'$%&%#**#'7+& A
+
6
4' 7:
4 '
/45+
$
460;
%'
>
9:&*
4#
*
#"& 85 #%-
:=$$6
#+
11.1.1
# '
"
&'$
-@
5 #$%&%& )*
%@
5
& *& ''
*
?@*
'7+'
$%& $0
-
*- $%&
6+ $
-
++ )
4 + '"
! #'
!
97
*&
#+>++ )
$+/$%
6
#+
#'
4*- $%& % #
060 ;
+
#
4 &
4#
$%'& *-
*& 60 ;
#
9-
11.1.2
/
!
# $
%
&'
#()
**
+
!'
* ,, -
&
0
1. %'$
- @
@*/'7+
#$%& %&
1.1 #@
> 660 ; 660 ;
#
'0 #/
@'
#% E;
'
E; '
/'@+ & A $%& %&
/
460 ;
'60 ; :- $%
4
$%& ++
*
()
+*43 5
( )
,, -
/
0
+*6*
7# &(
1.2 #@
+ 60 ; %60 ; #
4> &
'
'60;>
$
2.
- ++
One stop service > #
/
-
0 *- $%&
$%& / 7$>' %'/'''7: *& '%& *-
*
!
*'
#"+
- &
/$
& * $
#- *
-
*
3. #
# % #$%& ++
* (Hospital TB coordinator) ++
$
%$ %& % *%* ++ J
#+$
#:- 0
*
- A #='
%+++
'
#< 1
$
- %$-
-
- %60
6+#
%#$%&
%3.1
-
#+60 ;
$%&
+
$ A 6*
3.2 '
'$
- #@
@*
$%& %&
& :- $%
$ 3 (Cohort analysis) '+ 60 ; >
= 7
3.3 *& $#$%
& # 0 :4 '/:4 )*
+60 ;
(DOT) $%'&
+##$%&
4.
- DOT corner # % - *% %& %- *& '
'+ %#$%& *%& %-
60 ;
*& *+ &
4# 85
4.1 %'#
=
60;
4.2 %-<
'- 7
- & +- #-:- 0
* *& '60;
$##$%&
4.3 % Treatment card *&
##$%&
$:
$60 ;
98
4.4
60 ;
Daily dose % Drug packet *&
'#$%&60;
$'
&
60;>
9:&9 %'%-*&N
' 9:&
Drug packets %-'
@'
4.5 '
660 ; $%& J
#+$
24
& >
#))+ # *& '60;
+##$%&
#
#
%$%&
11.1.3 &&(
1. # $%&
$$% $%& %& *& $'7<
* +6
460;
$%&:-$%
4
6+*/
'7+
- (0%
$& $%) >
1.1 6
'0
$$%
'0 (TB04) *& $6'0 '
$%&
>
++ )
' 7 +6'0 '
>
' # 3
- $
6
#+6
>
#$%'&
%
%7- #$%'& > >
++
6' #*
%6>
++
*&
#
'
##
-
+ 60;
$ :-$%
4
*
1.2 #$%& ++
$:$%
4
(1.04) OPD Card
$
#@
7
,$%' (TB10)
$ 3 > TB 07, 07/1 08
'#
# 60* *&$'7<
4
* '
'
'?'
#
*- $%& *& +'7<
@*
#
2. '
N
'
'?'
#
'
'
'<
+$*/'
*
?< $% + 3
'7+@
5
(9:& + >
@*
. ) & %
4$%&
*& $'7<"
! # ' 7 #=$
"
! #>+& :11.1.4 !!
!!+*43 5 64
) (
(#
1. ?+$
4
+?% DOTS
#60;$$%&'60;
4$%&/0<+'?'
#$%&$
2. %''$%& %
(TB09)
3. 6 * 60 ; 6' # WJ < 69<
4.
+
4#7' OPD card (TB01)
$%>&
4
#:& *&>
4>70 $%
$:
$%' (TB10)
*&'
+ 6
460;
!
99
11.1.5 4&
&!/
% ' &' '
(Public Private MIX : PPM)
1. #
5> '
N
'
'?'
#
60'#
#
'& ' #
*/'7+
5 $ #+$
@ <+#'$7+& #
$%& %&
''
*
?@*'
'+
60 '
#$%&
$%& %& $
- @
5
+
6
#+
2. #
*
X0+
)*'#
'7*@
5
#'
4$7+&
3. * ' 7
*
5$/
'
60;>
4
#+ 60;$%&
%$%&60;
'
+
4$%&
*>
4. '
N
'
'?'
#
# %
(TB Network meeting / DOTS meeting) *& *
X+
>+ +6
4
>!"#'
& '+- ' + 3
5. @
5
#
''+
#+ DOT *&
##& A >+
#
5
11.2
,
+$%'&
"$
& &
%
4*$
!
'%& 60 $4 '@*
:$
# *-
#60
& (1) !"#
=$% +& :- )*
'7<*+- '< $
# %
60 ;
# *+ & :- '#
$/>$* 60 ;
'0$
& > 8-20 $ (2, 3)
$% & % 138 # %60
2 ' (4)
'=
+
$/>$ 6'
$%&%# $'?' $
,< $+? 9:&#
#=
'
"!"#
%#$%&
%$+$%&
#$$#$%&
+ '
# '
+$*$< $
,< '
N
'
'?'
#
,
11.2.1 , -
++)
+?%#;+
-
' #,< #$%& %
$/<' #$%& $%&> %$/<'$%&*
%
#/0<
100
#+ !
%
%
6$0 '%& '
;
9
+ =;
+ > 2 '
#<
+
4
11.2.2
0
&*60;
#$%&$:-$%60;
$%&'7*
9:& 60 ;
$%
$
& >
4*$<
#*60#'0 $6
#+ 60;
>
4
@
0
$#$
- #$%'& 7*#60 $%>&
$#$%&060;
%
#'#
60;
' #*- *&N
*-'060
& 9:&6
40
,<$%&*
%6' #/-'0
4#'0:- 7: '
#"
4#> 7: ,<$%& WHO
- > 85 &
*
'0 +- '< %60 ; '#:& >
#>'0
& A
11.2.3 &&(&
#$%*& #
'
"
+ DOTS
- A
% $%
A #$%&*60
$
$ 3
''
#
+$*$< $
,< '
'?'
#
$%&
- 0 $
- %'-
'?'
#
++#<
$
& >
#
- A
11.2.4 &!!
60 ;
$%& #*$4#
4 7 %$# #$%'& 7
*
# 0 /0<+'?'@ #*$%6& 0 ; >
4
*
'
'
#60 ; 1
#60 ; >+'% 1 '
#/0 <+$%6& 0 ; >
4
& 60 ; >
4$/0<+$%&
60 ; '
9:& +$%6& 60 ;
$% & %#
>
4 60;$%&
&*$4>
/0< +@ > $60;>
4#> 9:& %*
X'
60 ;
$
- # #@ *&
#60 ; >
4& >=%
!"# $'
(Social Stigma) *\+
$4=$$ '=
4
11.2.5
+
' 7+$
*- $%& A $%6&
* %0+$%&
*-$%& 9:&
'#
$
,< $
- %#- ' %+$/ + +6
#
*- $%& >
'
N
'?'
#
*&
#+
%'+$?+@*
5%
!
101
11.3
!*&'
!
%**$/*& $
- $%7& 0 8#
0
& #%- *& '#> # '#+'?'$%& % +
#$ & (Migrant worker) $%&&
&
:& 7 (cross - border population) %'@* 0$ %&
'@+
'+&
% carrier 60 + - $%%>
' %0
'0 $
#+!"#+
%
'< $ + A $%& *+ & '0:- $
#>$ %
'%& ;+$%& * #+- $%& E0 *+ & :- !"#'?'$%& +*+ &
'0:-0
&'
"$%&%&
##E; $
-
$'?'
'& A %+*& N
> '7<>
# 6% $'
& $/+>
!"#
$% *+ & :- $
-
+
$%& >
#'
6
'& '@* 0$ %&
'%& +'<& *\+ ''%& *+ & :- 6'
+
# *./.2539
43
#
*60 ;
1,451 60
372,242 # 390 '
# 5 - 6
>$ 60 ;
$%& *%'-
#"0
* %& > $% %& 0 #*
102
2. $%&
> >:-$% $
$%&>
$
(@$ )
3. +'6+8# (Illegal migrant worker)
4. Cross border population 7+&
& ' +
+ 6+8# $%&
+ - %- %
7'<*&
EN
-+ !"#'
6+ %& > '@*!"# 8%$%& %& @#
#$% & % 0 >
11.3.2 , ?@&
1. '
'?'
#
'
#
*- $%#&
+ + ' 0
$5 0 $% #
'@* EN
@$ ()
# 6% 0
6+ % + !"#&
2. #60 ;
'@*:- $% #
"$* $'7++*
3. EN
0;
'7+'?' $
- @
5
$% '7++ )*
4. '# (Active case finding)
#$%*& 60 ;
/
<'$7+& # #$%&%&
$'7++*60;
5.
W< .506 '
+$ $%
(TB03) )*
11.3.3 , ,
&
0
'
'?'
#
# %++
$%& % 5 6
#+ (National
Tuberculosis Programme)
$*- $%&
@$% & % #
@$
460; 6' # +60;:-$%
4
$ (
"%>)*)
10.3.4
&4& + (Monitoring and Evaluation)
j+
+
+ +6
+ $j+
+%
+
6
#+ +6
- % $
& > (0@6)
!
103
*
1. Drobniewski F. Tuberculosis in prison - the forgotten plaque. Lancet 1995 ; 346: 948-9.
2. Snider DE Jr, Hulton MD. Tuberculosis in Correctional Institutions. JAMA 1989; 261 : 436-7.
3. Braun MM, Truman BI, Maguire B, et al. Increasing incidence of tuberculosis in prison inmate population.
JAMA 1989 : 261 : 393-7.
4. +$*$< $
,< $ #>$. '7++60
60;
$/>$ *./.2540-2547. (
')
5.
'
'<
+$*/'
*
?< . 0 +
. $* : *+ *<$
,< ; 2546.
6. Pleumpanupat W, Jittimanee S, Akarasewi P, Rienthong S, Jittimanee S, Chiewlian Y, et al. Resistance
to antituberculosis drugs among smear-positive cases in Thai prisons 2 years after the implemen
tation of the DOTS strategy. Int J Tuberc Lung Dis 2003 ; 7(5): 472-7.
7. *=" +<+ X
104
13. +$/
.% %
# /%? *./. 2546
14. +$/
.@0=
*./. 2547
15. EN
$+$, '
+$ 2545
16. '' 0+
'
'?'
#
, 2544
17. 6'
+, $'?', 2539
!
105
106
&(
$ (TB 03)
$%
@'$%&
$: 06
460;
$$%& :-
$%
4$%& @ 60
6+
$ DTC 0
$:
4
70
$:6
$%
$
-$%& %:-$% %&
4 %- DTC
' 7
$%
%>-
$ 3 $
- 4 > #; (W< TB 07)
6' #%& & '+- '
4 (W< TB 07/1) 6
4
(W< TB 08) +6' 6'
'< (W< TB-HIV01)
W<
A % 0'
"$%& $
%1.
$%& :- $%
$%& DTC $%60 ;
$%
@
-
$%& :- $%
$%& + &
4
%
#
=>
2. $%
+ &
1
# %
>& A
$%
%-
$
-
$:
4
$%
@ $%
'0
$%
70#60 '
@
$%& DTC $$%60 ;
3. &60;$%&0 %&-' $%&0+$%&/
0 $%&
4
(>$ >
>$ 60
/$
,'7) >
1. 60 ;
# (#) #60 ;
$
- 2 +
# 60 ;
2. :- $%
4 :- $%@$
6 @$
3. '0$%&
4
4. 6' #*& + +6
4 & '+- ' $%& 5 '+- '
4
5. # 6
4> &
4
6.
$:
4*%& %- 9:& % %& *
60 ;
7.
$:
#:4 #+- HIV # CD4
8.
$:>
>
'N
)'
&('
3
(TB 04)
$%
'0
$%$%& %' ##-
$
-
%
++ )
+ 6
4 60
$ #$%&
'0 *./*$/*/. DTC ' 7
$%
'0%- *&
$#; 3 ' 7
' 0
$%
@>%
F> , & (TB 05)
'#
'' #*&
#60;
#
60 %''
*&
+ 6
4
CAT 1 : & '+- ' $%& 2 (3) #$%& 5 & '+- '
4$%& 6
107
CAT 2 : & '+- ' $%& 3 (4) #$%& 5 & '+- '
4$%& 8
CAT 3 : & '+- ' $%& 2
6
#+ %
$0 4 + #;
(W< TB 07) 6' #%& & '+- '
4 (W< TB 07/1)
6
4 (W< TB 08) +6' 6'
'<
3 - 6
(TB-HIV01)
$ A 3 %%
% *45 (F> TB07) DTC
#$%& ++
60
$
'6$%
@ $%
'0
(3 ) $%& *+& >*& +
6 #;
- A %+ #;
$
! TB/HIV+
& ! TB/HIV- Unknown 60 ; $%& :- $%
4
$@$ 9:& 60 ;
# ' # ( % - % '
"$+$'?' :
# % */60 ;
7 ) 60 ;
# ' #
9-60 ;
49-@#
#
49-@#
(' #) & A ' # (
< 15 > 15 )
$
- 60 %''
$%&' #60;$%&* 60;$%&
60;$%&
+ &4() ,4L ) #
0&&* * (F> TB07/1)
DTC
#$%&++
60
$'6' # &'+-'
4 60;$%&:-
$%' #*-
$ (
# ,
9- ,
49- @#
#
49-@#
)
&! TB/HIV+ &! TB/HIV- Unknown '$%
@
(3 ) $%& :- $%>#%- 6 - 9 %- '+& $%& %- '+$?+@* (
- )
4
@
- A
+
0 (F> TB08) DTC
#$%& ++
60
$
'6
4 &60;
4# $%& + 60;
# ' # 60;
# ' #
9-
49-@#
#
49-@#
(' #) &
! TB/HIV+ &! TB/HIV- Unknown '6$%
@ (3 )
$%& :- $%>#%- 12-15
+ +
&>
4 - 8 ( TB-HIV01)
+ + $?/'6' 6'
'<
3-6 $%6& #$%& ++
#$%&++'<60
$ *& +6+'7<
'<
% 2 ' '$%& %&
60 ;
'$%& %&
60 + - /60 ; '<
$
- 4 + = +6+
$ +6
9:& 4 A 3
108
-
1 > 4 (Quarterly report)
% $%& 1 : 1 - 31 ?
$%& 2 : 1 - 31 %
$%& 3 : 1 4 - 30 +7
$%& 4 : 1 8 - 30
,
4& + !4L 4 ,
#
'+- ' 3 60 '
$ +6j+
+
4 +
% 1/2550
1 . .-31
. . 48
(TB08)
2/2550
3/2550
4/2550
1/2551
1-7 . . 51
1 . .-31 . . 49 1 .
.-30 .
. 49 1 . .-30 .
. 49 1 . .-31
. . 49
(TB07/1)
(TB/HIV01)
(TB 07)
109
110
'7%
70#> '$%
'0$%
60;
$%&'7%
DTC '$ DOT 70
-j+
+#> ''
6
+
4$%&'7%
-''' # *&+ 6
4
$70 ##> 7 ' . %$$
$ DOT DTC %& ' .
#
:4 7%& +$/:- 0
+$/
%#%"&
.
&
RTC
PTC + RTC
DTC/TB clinic
'(
4
4
4
-
RTC
PTC (
) ! " . #
-
.
$#%
&'* DTC + TB Clinic ,/# +" &
'0'% 1 DTC + 2" %
34" &'*## TB Clinic + "
5 " .
111
112
113
114
1
AFB
ART
BCG
CAT
Category
CBC
CD4
Cluster of Differentiate 4
DTC
CUP
CXR
Chest x-ray
DST
EFV
Efavirenz
FDC
IUATLD
HAART
HIV
LTBI
MAC
DOT
NAPHA
NGOs
Non-Government Organization
NVP
Nevirapine
PAS
Para-Aminosalicylic Acid
PCP
PCU
PTB
Pulmonary Tuberculosis
115
116
TAD
WHO
.
.
.
.
.
!
117
118
//
( )
//
( )
#
$%&' 1.
2.
(# ) +
#
........................................
*
//
( )
//
( )
#
$%&' 1.
2.
(# ) +
#
.........................................
!"
119
120
121
122
%
& ++
......./........ ...............
/
District
TB No.
!(
' G:',
'., "+,+
K&
-
"
!(
' G:',
'., "+,+
K&
-
"
"
-
-1+-
!"
+ ........................................
',%.......................................
%
& ++
"
-
-1+-
!"
',%.......................................
......./ ...............
+ ........................................
........
TB 03 (TB Register)
/
District
TB No.
%
--
-
-
........../..........
'&
CAT................
.........................
.........................
.........................
/
%
--
-
-
6 (8)
--
- :;9
'&...............................
- (%4 :;9
'&...............................
. ......./............../..........
NAPHA No. .....................
%&!'(
0
2 (3)
5
- &-'
1
....../........../........
...........................................
2 .
...../........../........
...........................................
--
- :;9
'&...............................
- (%4 :;9
'&...............................
. ......./............../..........
NAPHA No. .....................
- &-'
Cu
Com
F
Die
Def
TO
....../....../......
....../....../......
....../....../......
....../....../......
....../....../......
....../....../......
%
........................
6 (8)
Cu
Com
F
Die
Def
TO
....../....../......
....../....../......
....../....../......
....../....../......
....../....../......
....../....../......
--
- Co-trimoxazole
?
,....................................
=4;9&+ >;' ?
%
--
- Co-trimoxazole
?
,....................................
=4;9&+ >;' ?
N
R
TAF
TI
TAD ...................... ...................... ...................... ......................
Lab. No. Lab. No. Lab. No. Lab. No.
O
Chronic
$
CD 4
P
EP
&"#(4.................
................................
%&!'(
2 (3)
5
N
R
TAF
TI
...................... ...................... ...................... ......................
TAD Lab. No. Lab. No. Lab. No. Lab. No.
O
Chronic
94
1
. ...../........../........
%...........................................
94
2
. ...../........../........
%...........................................
!"#
%%
+ '7%
.........................................
. ....../........../........
$
!%&! CD 4
P
EP
&"#(4.................
................................
!"#
%%
+ '7%
.........................................
. ....../........../........
1(9" /%&!%
1(9"
&!%
%%
,
...........
M
+
(K4
........../..........
'&
CAT................
.........................
.........................
.........................
1(9"
/%&!%
1(9"
&!%
%%
,
...........
M
+
(K4
/
" :
//
H.N.
Lab.
(Lab.Serial
No.)
-
!
"
"#
$!%
1
$!%
2
$!%
3
Spot Col. Spot Col. Spot Col.
123
124
125
108
126
109
127
128
X-ray
-
M Cul
!"
#"
"
$
% ""
&$'"%$
1 2 3 4 5 6
"$$'"
(outcome of
treatment)
Outcome of Treatment : 1 = Cure 2 = Complete treatment 3, Failure 4. Die 5. Defauit 6. Transfer (The outcome of treatment - not know)
:
(
) 2-3 //
!"
(Outcome of Treatment shoud be known (traced) within 2-3 months after the expected date of complete treatment)
#$%#
& ' *+
"
TB 10
129
130
TB - HIV 01
1
!
1.
!"
# $" %&
[ New M+, New M-, Relapse, EP, TAF, TAD, Others (M+, M-)
!
" !#$&% '!
' #*' !#'.'&/] 01
'2 30'4#'* 3 - 6 .'0 1 '
(
012'30'4*! 1 8.. 49 - 31 <.. 49 &'33=> TB/HIV 01 .1
!'01 31 0.. 50 $.1 #!
#'8G%'#&3/ HIV Counseling and Testing)
2.
!"
# $" %& ' (
$&%) !%*
!
#'01 1 013#/4#'8&*.2*0 (HIV counseling)
[#'3 &/''
01 0 !8&.'' !*0K'3&G'3%.'1 ]
+,
:
2 01 '2 30'4!3 #/4.1 G>
X 100
2 01 '2 30'4
3.
!"
(/
%)
%4)" %4'
!
#'01 2 0G1 #&%'8&!.*.2 *0 (HIV testing) [#'3 &/''
01 0 !8&.'' !*0K'3&G'3%.'1 ]
+,
:
2 0G1 #&8&!.*.2 *0
X 100
2 01 '2 30'4
4.
!"
%4'
%6
!
#'01 3 01 0 !8&!.*.2 *0K'3 [#'3 &/''
01 0
!8&.'' !*0K'3&G'3%.'1 ]
+,
:
2 0 1 !*0K'3
X 100
2 0G1 #&8&!.*.2 *0
131
5.
!"
/ + %4)" %4'
' !'/8!8
#'01 4 01 3 8QQ' 34 (# 8'S%38 %
G G'!G> G/'G> !8%8$UG$'<> 3)
+,
:
2 081 % *.2 *001 3 8QQ'
X 100
2 0 1 !*0K'3
6.
!"
/ + %4)" %4'
' /
CD4
#'01 4 01 3 8&3 CD4
01 3 8& CD4 #' 3 .'
'%14 .0 ! CD4 34 (''.&*!!#$%&
8& CD4 Q2/)
+,
:
2 081 % *.2 *001 3 8&3 CD4
X 100
2 0 1 !*0K'3
7.
!"
/ + %4)" %4'
CD4 /
250 cell/cu.mm
#'01 6 01 3 CD4 81/ 250 cell/cu.mm
+,
:
2 081 % *.2 *001 3 CD4 81/ 250 cell/cu.mm
X 100
2 081 % *.2 *001 3 8&3 CD4
8.
!"
/ + %4)" %4'
CD4 /
250 cell/cu.mm ' /'
(ARV)
#'01 7 01 3 ARV 34 (# 8'S%38 % G G'
!G> G/'G> !8%8$UG$'<> 3)
+,
:
2 081 % *.2 *0!03 CD4 81/ 250 cell/cu.mm
3 ARV
X 100
2 0 1 !*0K'3
132
2 / + %4)" /
%*
1. +/
%) %4'
%6
# :
01 33% post-test counseling !3 ! HIV positive # 8
3 %'&% Z
K' (
K'!#'3 #G#'G'01 1
)
:
8 % *.2 /
G> 01 3 !*0K'3'!
(
01 3 ! HIV positive #* ! 1 8.. 49 - 31 <.. 49 &'33=> TB-HIV 01
.1 !'01 31 0.. 50 $.1 #!
#'8G%'#&3/ TB screening)
2. / + %4)" /
%* +' (
$&%)
! @&*E %
!
#'# 1 013$&.1!3G4>\&&G01
5 '02
1. 08%8'%' 2 G> .
2. 08% 4' .
3. U#!*% 3
' .
4. 08#% *G%1 G$8%' .
5. 088% ' .
+,
:
8 % *.2 /
G> 01 33%3 #/4.1
!G4>&\ &G01
33%8&!. ! !*0K'3
X 100
+,
:
8 % *.2 /
G> 01 3 G4>!G8&S%38 %
X 100
33%8&!. ! !*0K'3
133
+,
:
8 % *.2 /
G>G01 8&S%38 % !$3
K'
X 100
33%8&!. ! !*0K'3
134
!" #$%&% '
()* +
135
136
/
+%K
! (Tuberculosis Supervision Check List)
1.
/+ & (TB 01)
S%38%
8 83
83'
3301$>G14
88
#G$3*.2 0 G. .''/
**'K'
G'3G''%'
&'0G1 '0'01 3'
#G
$3*.2G>#'*'!.'#'
8'.1
0.!4' 1 .'
#' CAT 1 ! CAT 2 #'001 G$3*.2 .1
G%2'G'
8&G$.18%8 !4
88
/'!
3' '8% 4
5 081 &
G$3*.2 4 8&G3
833
"81/ 5 3 01
# '3'03
$*.238&
K'
137
2. %
! (TB 03)
S%38%
8 83
83'
%1 !30'
! 1 .1 1 8!
!*.1 !01
*&'
! !4
3' !G$.18%8 !4#'
01
$3*.2 (/.1 !G$3*.2 )
3' !G$.1 8%8 !4#'
01
$3*.2
! !4
01 4 5 .'! 8&G
$3*.2 K' "4!!" !'2 30'
4# 34 CAT 2
0303330'*'G
8
081 &$3*.2
32'30'4
0
01 '2 30'K' Primary defaulter (8&$3*.2
83 4) .
03033 '8%402'30'
!* G $'<>3 '8% 4.
138
3. @&*
! (4 M%6'')
S%38%
8 83
K'
3*'%!G0"01 '%
8
3
88!3$30.1
3!4
8
3G/_%'43
.2 ! '
3$01$33
3%<0S%38%80$
3G/_0
G'3G''%'
'
3G/_8&G$.18%8
'4
3G/_'/
G G01 81/
5 ` #8&
3
.1G$'<>!
8%*.2 *0
139
4. %N&
!
S%38%
8 83
(3................)
0"34K'
.
0&/3_*0! !33%-&
83'
.
"34#'G (*.'2 , GG,
)%
01G.
0%$0$0&1 G/#*#'! 3-6 .'
.
0.G.1G$
#'!.
08&G3!4$0$1 G8
.
00#1 !& '' $.1 #G
'/#* ' Lot .'1 . (FEFO)
140
................
................
................
................
................
................
................
5. 4/
!
G+/ +
1. #
'
1.1 3!'*'G
8
&/''2G%2' ..........................'
3' ..................................'
G'013 .............................. 3.1 ......................................................
1.2
33%0G1 '3%G<G (Cohort jjj... 0 1 ')
38&G!&!U'> ................................................ ' (..........%)
38&G!&!U'>$.1%'%&Z ................................ ' (..........%)
$3*.2AFB ........................................................................................ ' (..........%)
018&G$3*.2 AFB 2'30'4 jjj............................... ' (..........%)
018&G$.1%'%&Z 3 3 2 jjj......................................... ' (..........%)
801 &G$.1 %'&% Z$3*.2 AFB 3 3 2 jjj..................... ' (..........%)
018&G$.18%843 2 2 ...................................... ' (..........%)
1.3 #3G8&G (Lab request: TB05)
0 #* $ jjjjjjjjjjjjjjjjjjjjjj............................jjj.
0#*
!!0
8
!!0
8 ...........................................................................................
jjjjjjjjjjjjjjjjjjjjjj................................jjjjjjj..
2.
O O* "%4)"
2.1 G
%$0$
3'
!3'xG
%$0$
3'
!3'*''G
3'
!3'x!'G
2.2 '&G!>
%$0$
%$0$
3'
!#*'% G0'
3'
!#*G '.1 0'
0! Serial Number
0 ! Serial Number
03' !8&G3'&G!>
03' !8&G3'&G!>
141
2.3 !&!U'>
!80 (Monocular)
!G8 (Binocular)
$0
$0
2.4 '2/G0*.2 AFB
%$0$
%$0$
#*'2/G0*.2 AFB 33'%<0 Ziehl-Neelsen
#*'2/G0*.2 AFB 33"'%<0 Kinyoun
'2/G0*.2 AFB #'G8~0#*'' 6 .''382 8' 0 1 !%8
'2/G0*.2 AFB #'G8~0#*'''%' 6 .''388' 0 1 !%8
'2/G0*.2 AFB
'2/G0*.2 AFB !
3. %$4/%
(TB 04)
83'
!
%1 ! Lab Serial Number 3>.1 1 8! `
!*.1 !
*&'
3' !G
83'
! !8&$3*.2 AFB 1+ 2+ 3+ G0
! !8&$3*.2 AFB G0//'2/%'
!3''2 30'
081 &$3*.2
142
#*
#*
4.
OO@J (Quality Control) /
%
OK*
1. $G3' '&G!>K'!!"8'.1
33'
2. 0"3G!>01 G08&*.2 AFB ! ' $.1
'$
3. 0#3'/GG!>$.1 '$ (QA1) #'`3
\&&3'
4. 0#3'/83 ! "%'8&G3G!>" (QA3) #'
`301 '
5. #'8&$.1 %'&% Z 08&G3 3 2
#'081 &G$3*.2 AFB
6. #'8&$.1 %'&% Z 08&G'
2 2 #'081 &$3*.2 AFB
#*
#*
143
144